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The overall objective of this study was to develop an in vitro based screening approach 
to determine the biotransformation rate constants of neutral hydrophobic organic 
chemicals in rats from rat liver S9 bioassays, and to test this screening approach by 
comparing in-vitro predicted biotransformation rates to in-vivo measured 
biotransformation rates. The test chemicals used for this study were pyrene, 
benzo(a)pyrene, hexachlorocyclohexane-beta, methoxychlor, mono-n-butyl phthalate, 
and 4-n-nonylphenol. In-vitro biotransformation rate constants were successfully 
obtained for all test chemicals and extrapolated to whole organism biotransformation 
rate constants using various IVIVE models. All the model outputs (IVIVE & QSAR) were 
compared to one another using descriptive statistical analysis. Various statistical 
parameters imply that all IVIVE models are very similar in performance. This indicates 
that the IVIVE-b model and IVIVE-Krause & Goss model (blood flow not considered), 
which require fewer biological parameters, could be used instead of the IVIVE-ph and 
IVIVE-Krause & Goss model (blood flow considered) for bioaccumulation assessment. 
Additionally, the IVIVE models were shown to perform slightly better than the QSAR 
models, indicating that the IVIVE models might be a better tool for estimating 
biotransformation rate constants compare the QSAR models. However, due to the 
variability in the in-vivo data and only a few chemicals being tested, a definitive 
conclusion cannot be made regarding which model performs the best. Furthermore, the 
IVIVE and QSAR models could be further upgraded in the future and only time will tell 
which models are the best for predicting whole organism biotransformation rate 
constants in rats.  
Keywords:  bioaccumulation; biomagnification, biotransformation; IVIVE; QSAR; rat 
liver S9 fraction; partition coefficient 
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In recent times, the continuous production and release of chemical substances 
has become a global concern. In Canada, there are approximately 23,000 substances 
on Canada’s Domestic Substance List that need to be categorized (CEPA 1999). On the 
market of the European Union, it is estimated that there are over 140,000 chemicals and 
700 new chemicals are being introduced into the market every year in the United States 
(production and emission of chemicals has been increasing) (Gobas et al., 2009). As 
hydrophobic chemicals enter the environment, bioaccumulation assessment becomes 
an important aspect in regard to conducting a risk assessment. Due to the 
bioaccumulation that may take place in biota, internal concentrations could become high 
enough to cause toxic effects (Gobas et al, 2009). Toxic substances could also 
bioaccumulate in organisms of higher trophic levels and cause harm to human health 
and wildlife. Additionally, long range transport could also take place, resulting in 
chemicals being found far from their point of origin (Artic and Antarctic) and persisting in 
the environment (Gouin et al., 2004). Therefore, chemicals are being assessed for their 
potential to be persistent (P), bioaccumulative (B), and toxic (T). 
1.1. Current Regulations of Anthropogenic Chemicals 
Both national and international regulatory programs have been developed to 
manage chemicals that pose a risk to human health and the environment. Regulatory 
agencies utilize a scientific approach to evaluate chemicals that have the ability to 
persist in the environment, bioaccumulate in organisms (or biomagnify in food chains), 
cause toxic effects, and be readily transported long distances (Lee, 2016). Persistence is 
determined by the length of time a chemical remains in a particular environment and is 
based on the substance’s half life in a particular medium. Bioaccumulation is defined as 
a process in which the chemical concentration in a living organism exceeds the chemical 
concentration in the respiratory medium, diet, or both (Gobas et al, 2009). Toxicity could 
be defined as the hazard a substance poses to human health and the environment (Lee, 
2016). The major regulatory programs that are addressing these chemicals at a global, 
regional, and national scale include the Stockholm Convention on Persistent Organic 
Pollutants, European Union's Regulation on Registration, Evaluation, Authorization and 
Restriction of Chemicals (REACH), United States Toxic Substances Control Act (TSCA), 
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Japanese Chemical Substances Control Law, and the Canadian Environmental 
Protection Act (CEPA) (Lee, 2016). 
The Stockholm Convention on Persistent Organic Pollutants is administered by 
the United Nations Environment Programme (UNEP), aiming to protect the environment 
and human health from persistent organic pollutants (POPs). It is a global treaty that was 
adopted in 2001 and it entered into force in 2004 (UNEP, 2009). According to the 
regulation, a chemical is persistent if it has a half life ≥60 days in water, ≥180 days in 
soils, or ≥180 days in sediments. If any of these criteria are met, the chemical is 
classified as persistent (UNEP, 2009). A chemical is bioaccumulative if the BCF ≥ 5000, 
BAF ≥ 5000, or logKow ≥ 5. For toxicity assessment, toxicity or ecotoxicity data that 
indicates adverse effects to human health, or the environment is required to classify a 
substance as toxic (UNEP, 2009). 
The Registration, Evaluation, Authorization, and Restriction of Chemicals 
(REACH) entered into force in 2007 by the European Union. In addition to PBTs 
(persistent, bioaccumulative, and toxic chemicals), there is also an assessment of vPvBs 
(very persistent and very bioaccumulative chemicals). A chemical is classified as 
persistent if its half life is ≥60 days in marine water, ≥40 days in freshwater, ≥180 days in 
marine sediment, ≥120 days in freshwater sediment, or ≥120 days in soil. A chemical is 
classified as very persistent if the half life is ≥60 days in either marine or freshwater, 
≥180 days in either marine or freshwater sediment, or ≥ 180 days in soil (European 
Chemicals Agency, 2017). For bioaccumulation assessment, a chemical is 
bioaccumulative if it has a BCF ≥ 2000 and very bioaccumulative if it has a BCF ≥ 5000. 
For air breathing organisms, a chemical is bioaccumulative if it has both a logKow ≥ 2 and 
a Koa ≥ 5 (European Chemicals Agency, 2017). For toxicity assessment, a substance is 
labelled as toxic if it has either a NOEC or EC10 ≤ 0.01 mg/L. A substance is also 
classified as toxic if it is carcinogenic, germ cell mutagenic, toxic for reproduction, or if 
there is evidence of specific organ toxicity after repeated exposure (European Chemicals 
Agency, 2017). 
The United States Toxic Substances Control Act (US TSCA) is a chemical 
management law administered by the United States Environmental Protection Agency 
(US EPA) and it came into effect in June 2016. The US EPA is required to identify 
existing substances as high priority or low priority substances and the high priority 
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substances will be subject to risk evaluations. According to the US TSCA, a substance is 
classified as persistent if it has a half life ≥ 60 days in water, sediment, or soil; or a half 
life ≥ 2 days in the air (USEPA, 1999). A substance is classified as bioaccumulative if it 
has a BCF or BAF ≥ 1000. For toxicity assessment, the substances are classified as 
toxic if they are known to cause or may cause significant adverse acute human health 
effects, adverse chronic human health effects (e.g., cancer or teratogenic effects, 
reproductive dysfunction, neurological disorders, and heritable genetic mutations), or 
adverse effects on the environment (USEPA, 1999). 
The Japanese Chemical Substances Control Law is used to regulate industrial 
chemicals in Japan (both new and existing chemicals) and it went into effect in 2010. In 
order to determine whether a chemical is persistent, the biological oxygen demand 
(BOD) is determined (by following OECD 310C test guidelines) (MHLW et al., 2011). 
The chemical is classified as not readily biodegradable if the BOD > 60% and readily 
biodegradable if BOD < 60%. For bioaccumulation assessment, a chemical is classified 
as highly bioaccumulative if the BCF ≥ 5000 and not highly bioaccumulative if the BCF ≤ 
1000 or the logKow < 3.5. Additionally, there is judgement considering other test data if 
1000 ≤ BCF < 5000 (MHLW et al., 2011). For toxicity assessment, the screening for 
toxicity is based on results of toxicity tests, including bacterial reverse mutation test, in 
vitro mammalian chromosome aberration test, repeated dose 28-day oral toxicity study 
in rodents, and reproduction/developmental toxicity screening test. Additionally, the 
screening for ecotoxicity is based on results from toxicity tests, including algal growth 
inhibition test, daphnids acute immobilization test, and fish acute toxicity test (MHLW et 
al., 2011). 
Lastly, the Canadian Environmental Protection Act (CEPA) was amended in 
1999 and is a part of the Canadian federal legislation to protect the environment and 
human health. In Canada, the domestic substance list was published in 1994 by 
Environment Canada and the list consists of approximately 23,000 substances that were 
manufactured in Canada between January 1984 and December 1986 (Lee, 2016). 
Health Canada and Environment and Climate Change Canada adhere to the regulations 
that are outlined in CEPA and the categorization (PBT) of all the substances on the list 
was completed by September 2006 (as required) (Lee, 2016). Environment Canada is 
responsible for identifying substances that are persistent, bioaccumulative, and 
inherently toxic. Health Canada is responsible for identifying chemicals that are 
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inherently toxic and have the greatest potential for human exposure. For the assessment 
of persistence, a chemical is classified as persistent if it has a half life ≥ 2 days in air, 
half life ≥ 182 days in water, half life ≥ 365 days in the sediment, or half life ≥ 182 days in 
the soil (Government of Canada, 1999; Government of Canada, 2000). For 
bioaccumulation assessment, a substance is classified as bioaccumulative if BAF ≥ 
5000, BCF ≥ 5000, or logKow ≥ 5. For toxicity assessment, substances are classified as 
CEPA-toxic if they have or may have an immediate or long-term harmful effect on the 
environment; or a substance that may pose a danger to human health or life. A 
substance is classified as inherently toxic to non-human organisms if LC50 or EC50 ≤ 1 
mg/L; or NOEC ≤ 0.1 mg/L (Government of Canada, 1999; Government of Canada, 
2000). 
1.2. Current Bioaccumulation Screening Criteria 
Limitations 
The current criteria for bioaccumulation assessment are displayed in Table 1.1. 
Bioaccumulation assessment relies on the bioconcentration factor (BCF), 
bioaccumulation factor (BAF), and the octanol-water partition coefficient (Kow). In 2017, 
the European Union included the octanol-air partition coefficient (Koa) and started using 
both the Kow and Koa value to assess bioaccumulation in air-breathing organisms 
(European Chemicals Agency, 2017). The BAF is the ratio of the chemical concentration 
in the organism to the chemical concentration in water at equilibrium, considering all 
routes of exposure. The BAF values are usually measured in field studies. The BCF is 
also the ratio of the chemical concentration in the organism to the chemical 
concentration in the water at equilibrium (Arnot & Gobas, 2006). The BCF takes into 
account all routes of chemical exposure except for a dietary route, and it’s usually 
measured under controlled laboratory conditions. The Kow value is the ratio of the 
chemical concentration in octanol to the chemical concentration in water at equilibrium 
(for an octanol-water phase system) (Arnot & Gobas, 2006). 
The problem with the current metrics to assess bioaccumulation is that they have 
some limitations, which may lead to substances getting miscategorized. The first 
limitation is that even though the BCF or BAF value is preferred over the Kow value, only 
a small percentage (3.7%) of the chemicals on Canadas Domestic Substance List of 
substances have empirical data that is available for the BAF and BCF value. Since most 
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chemicals don’t have empirical data available, the Kow value is used for bioaccumulation 
assessment. However, the Kow value on its own does not take biological factors like 
biotransformation into account. Since biotransformation is not considered, the 
bioaccumulation potential of a chemical can be overestimated, and this can 
mischaracterize the chemical's bioaccumulation potential (Arnot & Gobas, 2006). 
Biotransformation plays a very essential role in reducing internal tissue concentrations of 
chemical substances. If biotransformation is not considered, this could lead to false 
positives. For example, a chemical could have a very high Kow value and be rapidly 
metabolized. However, solely relying on the Kow value will lead to classifying the 
chemical as bioaccumulative when the chemical in not bioaccumulative due to its high 
biotransformation rate. The problem with current Canadian regulations is that the 
bioaccumulation potential for most chemicals is measured using the Kow value. An 
alternative approach is needed to assess bioaccumulation by using a bioaccumulation 
model that incorporates various chemical uptake and elimination processes. However, 
the problem is that the biotransformation rates are not available for majority of the 
chemicals, therefore the biotransformation rate constant is assumed to be zero for these 
models (Arnott & Gobas, 2004). This could lead to the same problem where the 
chemical's bioaccumulative potential may be overestimated since biotransformation is 
not taken into consideration. 
The second limitation of the current approaches to assess bioaccumulation is 
that a BCF test is conducted over a period of 3-6 months for a single chemical 
(Weisbrod et al., 2007). If there are approximately 700 new chemicals being introduced 
into the market every year (for the US alone), it will take a very long time assessing the 
bioaccumulative potential for all these new chemicals along with the chemicals that 
already exist on the market (Gobas et al., 2009).  
The third limitation regarding current bioaccumulation assessment approaches is 
that a BCF test uses a minimum of 108 fish per chemical (Weisbrod et al., 2007). 
Experiments that require a large number of organisms are not consistent with the 
replacement, refinement, and reduction of animal testing that is promoted by the 
European Union. Alternatives to animal testing are needed.  
The fourth limitation is that BCF tests cost approximately $125,000 per chemical 
(Weisbrod et al., 2007). If all the chemicals were to be assessed using these BCF tests, 
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it would be too expensive. A more cost-effective approach is needed to accurately 
assess chemicals for their bioaccumulative potential. 
A fifth limitation with the current bioaccumulation metrics is that they are limited 
to aquatic organisms. The assessment for non-aquatic organisms is based on the 
bioaccumulation criteria for aquatic organisms. The BCF, BAF, and Kow values are 
related to the chemical concentration in aquatic organisms in respect to the chemical 
concentration in water, assuming that the medium in which respiratory exchange occurs 
is water. However, for air breathing organisms, respiratory exchange does not take place 
in water, respiratory exchange occurs with the air. Also, studies in real food webs reveal 
that bioaccumulation is not solely a lipid-water partitioning process since 
bioaccumulation can be caused by biomagnification as well, resulting in an increase in 
chemical concentration with increasing trophic levels in food webs. Additionally, 
laboratory tests with fish show that poorly metabolizable, hydrophobic organic 
substances with a Kow ≥ 105 are proven to be susceptible to biomagnification in fish, 
whereas chemicals with a lower Kow value generally tend not to biomagnify in fish. 
However, this rule is not applicable for air breathing organisms (Kelly et al., 2007).  
In marine mammalian food webs (includes both water breathing 
invertebrates/fish and air breathing birds/mammals), it was shown that poorly 
metabolizable chemicals that have a Kow ≥ 105 and Koa ≥ 106 have a concentration in top 
predators up to 10,000 times higher than primary producers (Kelly et al., 2007). 
Furthermore, if the chemical has a Kow ≤ 105 and a Koa ≥ 106, it can still biomagnify and 
have concentrations in top predators greater than primary producers by 3000-fold (Kelly 
et al., 2007). Only when the Kow ≤ 102, no biomagnification occurs in this food web 
(regardless of whether the Koa ≥ 106) because air breathing organisms eliminate the 
chemicals via urinary and fecal excretion. For the terrestrial mammalian food web, it was 
also shown that chemicals with a Kow ≥ 102 and Koa ≥ 106 can biomagnify (Kelly et al., 
2007). The findings indicate that the B criteria for fish cannot be extrapolated to 
mammals since chemicals with a Kow ≤ 105 can biomagnify in mammalian food webs, 
even though they do not biomagnify in aquatic food webs. 
 Almost two-thirds of all organic chemicals used in commerce have a Kow ≥ 102 
and Koa ≥ 106 as one-third of all organic chemicals used in commerce have a Kow ≥ 105 
and Koa ≥ 106 (Kelly et al., 2007). This indicates that many chemicals used in commerce 
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could be harmful to mammals even though they are considered safe in fish (Kelly et al., 
2007). Therefore, both the Kow and Koa should be taken into consideration when 
screening chemicals for bioaccumulation. The European Union takes both parameters 
into account when assessing bioaccumulation for air breathing organisms (Table 1.1). 
However, the problem is that the Kow and Koa values alone aren't sufficient to accurately 
predict a chemical's bioaccumulative potential because the biotransformation rate 
constant is not taken into account, which will lead to overestimation of a chemicals 
bioaccumulation potential. Therefore, there is a need to develop an approach that could 
be used to assess bioaccumulation in air breathing organisms and at the same time, 
take biotransformation into account. 
Table 1.1. Current criteria to assess the bioaccumulative potential of 




Criteria (log values) Program 
Environment Canada Kow ≥ 100000 (5) CEPA (1999) 
Environment Canada BCF ≥ 5000 (3.7) CEPA (1999) 
Environment Canada BAF ≥ 5000 (3.7) CEPA (1999) 
European Union 
(bioaccumulative) 










≥ 100 (2) 

















BCF or BAF ≥ 5000 (3.7) Stockholm Convention 
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1.3. Biotransformation Rates of Xenobiotics 
Biotransformation is defined as the process by which a chemical substance gets 
transformed into another compound (metabolite) that is usually more hydrophilic (water 
soluble) than the parent compound. The hydrophilic metabolites that are formed are 
often more easily excreted by the organism (Toftgård & Gustafsson,1980). Even though 
biotransformation is involved in the detoxification of chemicals, there are cases where it 
could result in the bioactivation of compounds (making them more toxic than parent 
compounds) (Brandon et al., 2003). The primary organ responsible for metabolism is the 
liver, however biotransformation can also take place in other organs such as the lungs, 
heart, gastrointestinal tract, kidneys, skin, blood-brain barrier, etc (Anzenbacher & 
Anzenbacherova, 2001). Biotransformation enzymes can metabolize both endogenous 
and exogenous compounds. Often biotransformation involves a two-phase process to 
metabolize these compounds: phase I and phase II reactions (Toftgård & 
Gustafsson,1980). Phase I reactions increase chemical hydrophilicity by adding polar 
functional groups to the parent compound. Most of the final products of phase I reactions 
include functional groups such as -COOH, -OH, -SH, and -NH2. The three major types of 
phase I reactions include the oxidation, reduction, and hydrolysis reaction (Gibson & 
Skett, 2013). For phase I reactions, majority of the chemicals are metabolized by the 
cytochrome P450 enzyme system (CYPs) which are located predominantly in the 
membrane of the smooth endoplasmic reticulum. Due to their low substrate specificity, 
there is a broad range of substrates that can be metabolized (Gibson & Skett, 2013). 
Several isoforms of CYP enzymes are present throughout the body of mammals, but are 
most abundant in the liver, followed by the kidney and the gastrointestinal tract (Gibson 
& Skett, 2013). For a general CYP-mediated reaction, the reaction starts off when the 
xenobiotic substrate binds to the active site of the enzymes along with nicotinamide 
adenine dinucleotide phosphate (NADPH), and oxygen. This results in the formation of 
NADP+, water and the -H group on the xenobiotic gets replaced with an -OH group 
(Gibson & Skett, 2013). 
In phase II reactions, the functional group that was added by the phase I 
enzymes could be recognized by the phase II enzymes to initiate an enzymatic reaction. 
However, there are molecules that can directly go through phase II reactions as well. In 
phase II reactions, an endogenous molecule gets added to the metabolite formed from 
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the phase I reaction (or parent compound), resulting in a product that is very hydrophilic 
with a high molecular weight. This greatly enhances the transport and elimination rates 
of these conjugated products. Unlike phase I reactions that can both detoxify or 
bioactivate the exogenous compounds, phase II reactions result in just the detoxification 
of xenobiotics (Gibson & Skett, 2013). Most of the phase II enzymes are located in the 
cytosolic portion of the cell. One of the major pathways for phase II biotransformation is 
the glucuronidation reaction which involves the enzyme UDP-glucuronyl transferase. An 
example of a glucuronidation reaction is when morphine’s phenolic and secondary 
alcohol groups get conjugated with uridine diphosphate glucuronic acid (UDPGA). 
(Camille, 2015). UDP-glucuronyl transferase is located in the endoplasmic reticulum 
(ER), with its catalytic domain exposed to the lumenal side of the ER membrane 
(Kinosaki et al., 1993). For the glucuronidation reaction, the functional groups that are 
recognized include -OH, -COOH, -NH2, and -SH. The substrates for this reaction include 
the xenobiotic along with uridine diphosphate glucuronic acid (UDPGA). The glucuronic 
acid component of uridine diphosphate glucuronic acid gets transferred to the xenobiotic 
by the enzyme, resulting in a very hydrophilic product (Gibson & Skett, 2013). Another 
pathway for phase II biotransformation includes the sulfate conjugation reaction which 
involves the enzyme sulfotransferase. The reactants for this enzyme include the 
xenobiotic along with 3'-phosphoadenosine-5'-phosphosulfate (PAPS). A sulfo group 
from PAPS gets transferred to the xenobiotic to form a hydrophilic product, which then 
gets transported and eliminated (Gibson & Skett, 2013). For example, minoxidil (a 
pharmaceutical) can be converted into minoxidil-sulfate through this reaction (Camille, 
2015). The glutathione conjugation reaction is another example of a phase II reaction 
that takes place and involves the enzyme glutathione S-transferase. Substrates that are 
recognized by this enzyme include epoxides and halides. The substrates for this enzyme 
include the xenobiotic along with glutathione (GSH). The product for this reaction is a 
glutathione conjugate which gets excreted (Gupta, 2016). Other phase II 
biotransformation pathways include glycoxidation, amino acid conjugation, acetylation, 
and methylation (Gibson & Skett, 2013). 
There are some differences in the composition, expression, and catalytic activity 
of enzymes that have been observed between species. For example, CYP3A is the most 
abundant CYP subfamily in the human liver and CYP2C is the most abundant subfamily 
in the rat liver (Han et al., 2009). There are also some differences between the fish liver 
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and rat liver. It has been noted that fish appear to have a homogenous distribution of 
biotransformation enzymes in the liver and a lower capacity than mammals to 
metabolize xenobiotic substances (Wolf & Wolfe, 2005). It has been speculated that this 
may be due to the fact that fish can eliminate parent compounds via their gills unlike 
mammals, hence resulting in the mammals relying more on liver enzymes to eliminate 
xenobiotics (Wolf & Wolfe, 2005). More specifically, it was noted in a study by Han et al. 
(2009) that the activity of CYP1A and CYP3A in the rainbow trout liver microsomes and 
S9 was significantly lower than the activity in rat liver microsomes and S9. Another 
difference is that fish have a lower liver to body weight ratio than mammals. Fish also 
have a 1/2 to 1/4 less liver perfusion than mammals and bile formation in fish is 50-fold 
slower compared to mammals (Wolf & Wolfe, 2005). 
Since the biotransformation rates of exogenous compounds could possibly vary 
between fish and air breathing organisms, it’s important to develop methods to measure 
biotransformation rate constants for air breathing organisms. As mentioned previously, 
one of the limitations for bioaccumulation assessment is that the current metrics are 
limited to aquatic species and are being used to assess bioaccumulation in air breathing 
organisms. There is a need to develop methods that are specific to air breathing 
organisms. In June 2018, the Organisation for Economic Co-operation and Development 
(OECD) developed a test guideline (319B) to determine the in vitro biotransformation 
rate constant using the rainbow trout liver S9 fraction. Currently, there is no universally 
accepted protocol developed to assess biotransformation rates in mammals. 
1.4. Methods to Determine Biotransformation Rate 
Constants for Mammals 
To assess bioaccumulation in mammals, a rat BMF model could be used as an 
alternative to in vivo testing (Armitage & Gobas, 2007). The model consists of various 
uptake and elimination pathways and the organism's biotransformation rate constant is 
one of the inputs for the model. The biotransformation rate constant needs to be 
measured/predicted before it can be used as an input (Armitage & Gobas, 2007). 
Biotransformation rates could be calculated via in-vivo experiments, but the experiments 
can be expensive, time consuming, and require a large number of organisms. Alternative 
approaches are needed so chemicals could be assessed more rapidly, with less 
organisms being used, and in a cost-effective manner (Lee, 2016). One way to fulfill 
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these requirements is with in-silico approaches known as Quantitative Structure-Activity 
Relationships (QSAR), that are now largely accepted as cost effective solutions in 
bioaccumulation science. There are various types of QSARs, but generally a QSAR 
model is based on different types of molecular descriptors and their relationship to 
biological activity (Papa et al., 2018). In order to calculate the whole organism 
biotransformation rate constant using a QSAR, the chemical structure of a compound 
will be used to predict the whole organism biotransformation rate constant (Papa et al., 
2018). Arnott et al. (2014) developed a QSAR model that could be used to predict the 
whole organism biotransformation rate constants for humans. There was data collected 
for over 1000 chemicals from the literature and the data then gets split up into a training 
set and prediction set. The training set is used to calibrate the QSAR model using an 
algorithm and the prediction set is used to test the model to see if the predicted values 
are similar to the observed values from the literature. To calibrate the model using the 
training set, the Iterative Fragment Selection (IFS) system was used (Arnott et al., 2014). 
In this approach, the chemical gets broken into single unit fragments (breaking of single 
and aromatic bonds). Then software is used to determine the relationship between the 
functional groups and the biotransformation rate constant. The QSAR model is then 
tested using a functional set as the predicted values are compared to the observed 
values (Arnott et al., 2014). Papa et al. (2018) also developed four QSAR models to 
predict biotransformation rate constants in humans. To calibrate the models using the 
training set, global molecular descriptors are used. Molecular descriptors are numerical 
values that quantitatively describe chemical and physical properties and can be defined 
as mathematical representations of molecular information (Chandrasekaran et al., 2018). 
One limitation of these in-silico approaches is that the data collected from literature 
needs to be high quality. For some studies, there could be experimental conditions that 
are not reported, resulting in variability. There are various factors that could affect the 
whole organism biotransformation rate constant (dose, route of administration, etc). 
These factors could vary from study to study, which could affect the uncertainty and 
accuracy of the model predictions (Arnot et al., 2008; Lee, 2016). Another limitation is 
that new chemical classes may not be represented in the QSAR training set, indicating 
that the application of the QSAR to new chemical classes is limited (Lee, 2016).  
Another cost-effective approach used to estimate the whole organism 
biotransformation rate constant is the use of in vitro assays. In vitro experiments are 
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used to measure the in vitro biotransformation rate constants which then are converted 
into the whole organism biotransformation rate constant by an in vitro to in vivo 
extrapolation (IVIVE) (Nichols et al., 2013). In the pharmaceutical field, an IVIVE is 
widely used to predict the hepatic clearance of drugs for clinical applications (Rane et 
al., 1977; Houston, 1994; Jones & Houston, 2004). In regard to bioaccumulation 
assessment, an IVIVE model for fish has recently been developed by Nichols et al. 
(2006) and refined in 2013 (Nichols et al., 2013). The in vitro intrinsic clearance is 
measured in vitro using a substrate depletion approach. A substrate depletion 
experiment could be performed using the S9 subcellular fractions, microsomes, or 
hepatocytes (Lee, 2016). The in vitro clearance is then converted into the hepatic 
clearance, which is then converted to the whole organism biotransformation rate 
constant (Nichols et al., 2013). Other IVIVE models developed in recent times for 
mammals include the IVIVE-b model developed by Lee et al (2017) and Krause & Goss 
(2018) models. The in vitro biotransformation must be measured prior to the use of these 
models. As previously mentioned, an in vitro approach has been developed for rainbow 
trout but there is no universally accepted protocol developed to assess biotransformation 
rates in mammals. 
1.5. Research Objectives 
The main objective of this project was to develop an in vitro based screening 
approach (solvent delivery-based method) to measure the biotransformation rate 
constants of neutral hydrophobic organic chemicals in rats from rat liver S9 bioassays 
and to test this screening approach by comparing in-vitro predicted biotransformation 
rates to in-vivo measured biotransformation rates. Specific objectives for this project are: 
1. Measure in-vitro biotransformation rate constants and extrapolate 
them to in-vivo biotransformation rate constants using an in-vitro to in-
vivo extrapolation (IVIVE) model. 
2. Compare whole organism biotransformation rate constants obtained 
from the IVIVE- b model to whole organism biotransformation rate 
constants obtained from other models that are available for mammals. 
3. Compare in-vivo biotransformation rates obtained from in vivo studies 
(from literature) to whole organism biotransformation rate constants 
(obtained from the models). 
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To accomplish this, the solvent phase dosing method which has been developed 
by Lee et al (2012) was used and slightly modified to measure liver S9 biotransformation 
rate constants of very hydrophobic test chemicals. In the solvent delivery-based method, 
a chemical is introduced into a small volume of organic solvent and added to the rat liver 
S9 homogenate to determine the in vitro biotransformation rate constant. Even though 
hepatocytes and microsomes could be used for the substrate depletion experiments, the 
S9 fraction was used because it's both easy to prepare and use. Additionally, the S9 
fraction contains both the cytosolic and microsomal enzymes, therefore both the phase I 
and phase II enzymes are involved in metabolizing the chemicals being tested (Kaplan, 
2018). For this study, the test chemicals used to test the solvent phase dosing method 
are pyrene, benzo(a)pyrene, hexachlorocyclohexane-beta (beta HCH), methoxychlor, 
mono-n-butyl phthalate, and 4-n-nonylphenol. 
Next, the in vitro biotransformation rate constants obtained from the solvent 
phase dosing method will then be input into four different IVIVE models to calculate the 
whole organism biotransformation rate constants. These values will be compared to one 
another and compared to the whole organism biotransformation rate constants obtained 
from the QSAR models. Lastly, the values obtained from all nine models will be 
compared to in vivo elimination rate constants obtained from the literature. 
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2. Materials and Methods 
2.1 Test Chemicals 
Pyrene, benzo(a)pyrene, methoxychlor, 4-n-nonylphenol, 4-tert-octylphenol, 
alamethicin, N,O-bis-(trimethylsilyl)-trifluoroacetamide (BSTFA), and deuterated (d-12) 
chrysene were purchased from Sigma-Aldrich (St Louis, Missouri, USA). 
Hexachlorocyclohexane-beta (beta HCH) was obtained from Fluka (Buchs, St. Gallen, 
Switzerland). Mono-n-butyl phthalate and mono-2-ethylhexyl phthalate were prepared at 
BASF Corporation (Pasadena, Texas, USA). Trimethylsilyl diazomethane (TMSDM) was 
purchased from Fisher Scientific (Waltham, Massachusetts, USA). Hexanes, acetonitrile, 
methanol, ethyl acetate, toluene, potassium hydroxide (KOH), and potassium phosphate 
(monobasic) (KH2PO4) were obtained from Caledon Laboratories Inc (Georgetown, 
Ontario, Canada). Potassium phosphate (dibasic) (K2HPO4) was obtained from 
Anachemia Canada (Lachine, Quebec, Canada). All other chemicals, if not specified, 
were purchased from Sigma-Aldrich (St Louis, MO, USA). 
2.2 Test Organism 
Male Sprague-Dawley rats were acquired from Charles River laboratories 
(Wilmington, Massachusetts, USA) and they weighed around 370-440 g body weight. 
The rats were housed at the Animal Resource Centre at Simon Fraser University for at 
least seven days upon arrival. They were fed Laboratory Rodent Diet 5001 (Lab Diet, St. 
Louis, Missouri) and allowed food and water ad libitum. The rats were maintained in the 
animal rooms at a constant temperature of 19-23 oC and a constant humidity of 45-55 % 
under a 12 h dark/light cycle.  
2.3 Preparation of Liver S9 Sub-Cellular Fractions 
The liver S9 subcellular fractions were prepared by Yung Shan Lee. Wash buffer 
was prepared by adding 2.30 g KCl (154 mM), 1.062 g of KH2PO4 (39 mM), and 2.124 g 
of K2HPO4 (61 mM) into 200 mL of DI H2O (adjusted to a pH of 7.4). Homogenization 
buffer was prepared by adding 1.15 g KCl (77.1 mM), 0.531 g of KH2PO4 (19.5 mM), 
1.062 g of K2HPO4 (30.5 mM), and 8.5575 g sucrose (125 mM) into 200 mL of DI H2O 
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(adjusted to a PH of 7.4). The rats were anesthetized using isoflurane and euthanized 
with CO2. Death was confirmed by opening of chest and removal of heart (Lee et al., 
2012). An incision was made to expose the internal organs and the ice-cold wash buffer 
was injected into the hepatic portal vein to perfuse the liver (until the liver was pale in 
color). The liver was then excised, followed by immersing the liver into the wash buffer. 
There were nine rats sacrificed in total (three livers were needed to prepare one batch of 
S9 and there were three batches of S9). The liver for each rat was weighed, minced on 
ice with a razor blade, and homogenized on ice using a Potter-Elvehjem glass tissue 
grinder with a Teflon pestle (Kontes, Vineland, New Jersey) (Lee et al., 2012). The liver 
was homogenized in the homogenization buffer (1 g liver: 1 mL buffer). Since one batch 
of S9 consisted of three livers, the homogenate from the three different livers was pooled 
together and transferred to a 50 mL Oakridge centrifuge tube (Nalgene Labware; BW, 
Germany). The liver homogenates were centrifuged at 9000 x g for 20 minutes at 4 oC. 
The 9000-g supernatant fraction (S9) was collected and transferred to microfuge tubes 
and stored at -80 oC until use (Lee et al., 2012). 
2.4 Incubations 
2.4.1 Incubation experiment 
Phosphate buffer (100 mM KPO4) was prepared by adding 0.2655 g of KH2PO4 
and 0.5310 g of K2HPO4 into 50 mL of DI H2O (adjusted to a pH of 7.4 using KOH). All 
cofactors used for the incubation experiment were purchased from Sigma-Aldrich (St 
Louis, Missouri, USA). The cofactors include nicotinamide adenine dinucleotide 
phosphate (NADPH), uridine diphosphate glucuronic acid (UDPGA), glutathione (GSH), 
and 3’-phosphoadenosine-5’-phosphosulfate (PAPS). The NADPH, UDPGA, and GSH 
were stored at -20 oC and PAPs was stored at -80 oC (OECD, 2018). The details for the 
cofactor mix (prepared in phosphate buffer with a total volume of 1 mL) can be seen in 
Table 2.1. Since UDP-glucuronosyltransferase (UGTs) is located on the endoplasmic 
reticulum (ER) membrane, with the catalytic domain exposed to the luminal side of the 
membrane, UDPGA needs to get into the lumen of the ER in order to interact with the 
enzyme. When microsomes are formed in the S9 fraction, this often yields lower levels 
of activity compared to microsomes that are treated with a membrane-disrupting agent 
(a phenomenon called latency) (Ladd et al., 2016). For UGTs, this phenomenon is 
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attributed to rate limitations which are caused by the restricted transport of UDPGA 
across the ER membrane, and without UDPGA, the enzyme cannot react with the test 
chemical (Ladd et al., 2016). For this study, a membrane disrupting agent called 
alamethicin was used to enhance the activity of UGTs (OECD, 2018). Alamethicin 
(dissolved in methanol) was diluted with buffer on the day of the incubation and added to 
the incubation mixture. All test chemicals were dissolved in toluene for storage and 
diluted in acetonitrile before being added to the incubation vials to achieve a desired 
starting concentration for the test chemical. The internal standards were dissolved in 
toluene, diluted in acetonitrile, and added to 2 mL amber autosampler vials (Agilent; 
Mississauga, ON, Canada) that were stored on ice (OECD, 2018). Prior to the incubation 
experiments, alamethicin was added to the liver S9 fraction and preincubated on ice for 
15 minutes. Then the cofactor mix was added, and the vials were preincubated for 5 
minutes (37 oC, 80 r.p.m.) prior to adding the test chemical. Incubation experiments were 
conducted in a water bath (Grant OLS200, Cambridge) at 37 oC as the vials were being 
constantly shaken (80 r.p.m) for the entire incubation period. After the test chemical was 
added to the incubation vial, the vial was immediately vortexed for 5 seconds and the 
reactions were initiated (OECD, 2018). The incubation experiment for each test chemical 
had the same general procedure with a few modifications for mono-n-butyl phthalate and 
4-n-nonylphenol.  
Table 2.1. Preparation of the cofactor mix. The cofactors were added to 
phosphate buffer to get the final concentrations. 
Cofactor Amount added Molecular Weight Final Concentration Reference 
NADPH 0.0167 g 833.35 g/mol 2.0 mM (OECD, 2018) 
UGPDA 0.0129 g 646.23 g/mol 2.0 mM (OECD, 2018) 
GSH 0.0154 g 307.32 g/mol 5.0 mM (OECD, 2018) 
PAPS (10 mM) 100 µL 507.26 g/mol 0.1 mM (OECD, 2018) 
2.4.1.1 Incubations for benzo(a)pyrene, beta-
hexachlorocyclohexane, and methoxychlor 
After the test chemical was added to the incubation mixture to initiate the 
reactions (37 oC, 95 r.p.m.), the reactions were terminated by transferring a subsample 
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of the incubation mixture into ice cold acetonitrile. At each time point, 500 µL of the 
incubation mixture was transferred to the 2 mL amber autosampler vials (Agilent; 
Mississauga, ON, Canada) containing 300 µL of ice-cold acetonitrile with the internal 
standard (OECD, 2018). The internal standard used for all three test chemicals was 
chrysene d-12. Consequently, 800 µL of hexane was added to the same 2 mL amber 
autosampler vials and the vials were vortexed by hand for 10 seconds. All vials were 
then vortexed for 10 minutes at 2400 rpm (VWR multi-tube vortexer, Mississauga, ON, 
Canada), followed by a 20-minute centrifugation (Centra CL2 benchtop centrifuge, 
Thermo IEC, USA) at 3000 rpm. After centrifugation, the vials consisted of an aqueous 
layer (bottom layer) and a hexane layer (top layer). The upper layer hexane extract 
(>400 µL) was transferred to new 2 mL amber autosampler vials that were loaded onto 
the GC/MS.  
2.4.1.2 Incubation for mono-n-butyl phthalate 
After adding the test chemical to the incubation mixture to initiate the reactions 
(37 oC, 95 r.p.m.), the reactions were terminated by transferring 500 µL of the incubation 
mixture into 1000 µL of ice-cold acetonitrile with the internal standard (in the 2 mL amber 
autosampler vials). The internal standard used for this test chemical was mono-2-
ethylhexyl phthalate. All vials were then vortexed for 10 minutes at 2400 rpm (VWR 
multi-tube vortexer, Mississauga, ON, Canada), followed by a 20-minute centrifugation 
(Centra CL2 benchtop centrifuge, Thermo IEC, USA) at 3000 rpm. A pellet formed at the 
bottom with the supernatant consisting of acetonitrile (containing test chemical and 
internal standard). Exactly 500 µL of the supernatant was transferred to new 2 mL amber 
autosampler vials. The supernatant was dried down with a steady steam of N2 gas at 
room temperature (2 psi). Next, the chemicals had to be derivatized. Derivatization is the 
modification of a compound in order to make it more suitable to be analyzed using 
chromatographic methods. The derivatization agent used was trimethylsilyl 
diazomethane (TMSDM), which is used to methylate monoesters by reacting with the 
hydroxyl group of mono-alkyl phthalate esters (MPEs) and converting them into methyl 
esters (Niino et al, 2002). The derivatization reaction for mono-n-butyl phthalate can be 
seen in Figure 2.1. The purpose of this reaction is to generate a stable product with 
higher volatility, reproducible yields, no side reactions, and a compound that could be 
detected easily at low concentrations (Blau and Halket, 1993). The derivatization 
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reaction was carried out by resuspending the dried down samples with 500 µL ethyl 
acetate, 100 µL methanol, and 25 µL of TMSDM, followed by vortexing the vials for 10 
seconds. The vials were then gently rotated for 30 minutes at room temperature and all 
the samples were then dried down with a steady steam of N2 gas (2 psi). Finally, the 
samples were then resuspended with 500 µL of hexane and loaded onto the GC/MS 
(Sura, 2007). 
 
Figure 2.1. Derivitization reaction carried out for mono-n-butyl phthalate. 
2.4.1.3 Incubation for 4-n-nonylphenol 
After the test chemical was added to the incubation mixture to initiate the 
reactions (37 oC, 95 r.p.m.), the reactions were terminated by transferring 500 µL of the 
incubation mixture into 1000 µL of ice-cold acetonitrile with the internal standard (in the 2 
mL amber autosampler vials). The internal standard used for this test chemical was 4-
tert-octylphenol. All vials were then vortexed for 10 minutes at 2400 rpm (VWR multi-
tube vortexer, Mississauga, ON, Canada), followed by a 20-minute centrifugation 
(Centra CL2 benchtop centrifuge, Thermo IEC, USA) at 3000 rpm. A pellet was formed 
with the supernatant consisting of acetonitrile (containing test chemical and internal 
standard). Exactly 500 µL of this supernatant was transferred to new 2 mL amber 
autosampler vials. The supernatant was dried down with a steady steam of N2 gas at 
room temperature (2 psi). Since 4-n-nonylphenol is a polar compound, a derivatization 
reaction was required. N,O-bis-(trimethylsilyl)-trifluoroacetamide (BSTFA) was used as 
the derivatization agent to replace the hydroxyl group on 4-n-nonylphenol (and 4-tert-
octylphenol) with a trimethylsilyl (TMS) group (DiMauro, 2012). The derivatization 
reaction for 4-n-nonylphenol can be seen in Figure 2.2. The derivatization reaction was 
carried out by resuspending the dried down samples with 100 µL BSTFA + 1% TMCS, 
followed by vortexing the vials for 10 seconds. The samples were then placed in a 
beaker consisting of water boiling at 70 oC for 1 hour. Then the samples were cooled 
down at room temperature for 5 minutes and dried down under a steady steam of N2 at 
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room temperature (2 psi). Finally, the samples were resuspended with 500 µL of hexane 
and loaded onto the GC/MS (DiMauro, 2012). 
 
Figure 2.2. Derivitization reaction carried out for 4-n-nonylphenol. 
2.4.1.4 Negative Controls 
Heat inactivated S9 (HI-S9) was prepared by boiling the rat liver S9 for 15 
minutes at 100 oC. For all incubation experiments, there was a negative control vial 
containing the heat inactivated S9 (HI-S9), test chemical, and phosphate buffer. The 
purpose of the negative control vial was to control for additional factors that may affect 
the in-vitro depletion experiments (OECD, 2018). 
2.4.1.5 Positive Controls 
Pyrene was used as a reference chemical to monitor any changes in activity 
throughout experimentation and run parallel to the test chemical incubations. For all 
incubation experiments, there was a vial containing the active S9, pyrene, cofactor mix, 
alamethicin, and phosphate buffer. Pyrene was added to both the active S9 vial and the 
HI-S9 vial (negative control). The main purpose of the reference chemical is to monitor 
any differences in enzymatic activity between the depletion rate of the test chemicals in 
different batches of S9 (OECD, 2018). 
2.4.2 Preliminary experiments 
For the preliminary experiments, there were two vials pre-incubated for 5 minutes 
(37 oC) prior to the incubation experiment. The first vial contained the active S9, test 
chemical, NADPH, and phosphate buffer. The second vial contained the HI-S9, test 
chemical, and phosphate buffer. The purpose of the preliminary experiments was to 
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determine optimal conditions (starting concentration of test chemical, internal standard 
concentration, time points, GC/MS method) for the final experiments (OECD, 2018).  
2.4.3 Final experiments 
For the final experiments, the incubations with the test chemical and pyrene were 
completed in triplicate (n=3). The incubation details for each chemical are shown in 
Table 2.2. The incubation experiments with benzo(a)pyrene, beta-
hexachlorocyclohexane, methoxychlor, mono-n-butyl phthalate, and 4-n-nonylphenol 
consisted of three different incubation mixtures: 1) active S9 incubation vial containing 
the active S9, test chemical, cofactor mix, alamethicin, and phosphate buffer; 2) negative 
control vial containing the heat inactivated S9 (HI-S9), test chemical and phosphate 
buffer; and 3) reference chemical vial containing active S9, pyrene, cofactor mix, 
alamethicin, and phosphate buffer. The incubations for each test chemical had the same 
general procedure with a few modifications for mono-n-butyl phthalate and 4-n-
nonylphenol. The final protein concentration of S9 was 1 mg/mL for all the subsampling 
incubation vials (OECD, 2018). 
Table 2.2. Overview of incubation details for each test chemical. The final 









Pyrene 0.05 1 1, 2, 3, 4, 5, 6, 7 




5, 15, 30, 45, 60, 75, 
90 
Methoxychlor 0.5 1 0.5, 1, 2, 3, 4, 5, 7 
Mono-n-butyl phthalate 0.5 1 2, 4, 6, 8, 10, 12, 14 
4-n-nonylphenol 1 1 2, 4, 6, 8, 10, 12, 14 
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2.5 GC/MS Chemical Analysis 
All the samples were analyzed using an Agilent 6890 gas chromatograph (GC) 
coupled to an Agilent 5973 mass spectrometer (MS) (Agilent, Mississauga. ON, 
Canada), and the GC had a cool on column injection port. When the samples were 
loaded onto the GC/MS, 1 µL of the sample was injected. The chemicals were separated 
on: a HP-5MS 5% phenyl methylpoly-siloxane-coated column (30m x 0.25mm inner 
diameter, 0.25mm film thickness), connected to a fused silica deactivated guard column 
(5m x 0.53 mm inner diameter). The carrier gas used was helium with a flow rate of 
1mL/min. The measurements were completed using a 70 eV ion energy, and an ion 
source temperature of 230 oC. For pyrene, benzo(a)pyrene, beta-HCH, and 4-n-
nonylphenol, the initial temperature was 60 oC for 1 min followed by a temperature ramp 
of 30 oC/min, to a maximum temperature of 290 oC (held for 8 mins). For methoxychlor, 
the initial temperature was 60 oC for 1 minute followed by a temperature ramp of 35 
oC/min, followed by another temperature ramp of 16 /min, to a maximum temperature of 
290 oC (held for 8 mins). For mono-n-butyl phthalate, the initial temperature was 60 oC 
for 1 min followed by a temperature ramp of 35 oC/min, to a maximum temperature of 
290 oC (held for 8 mins). All the test chemicals and internal standards were measured at 
select ions: m/z 202 for pyrene, m/z 252 for benzo(a)pyrene, m/z 219 for beta-HCH, m/z 
227 for methoxychlor, m/z 163 for mono-n-butyl phthalate, m/z 179 for 4-n-nonylphenol, 
m/z 240 for chrysene d-12, m/z 163 for mono-2-ethylhexyl phthalate, and m/z 207 for 4-
tert-octylphenol.  
2.5.1 Calibration Curves 
For each test chemical (with internal standard), a calibration curve was 
constructed at the time of the incubation. There were six different concentrations of the 
test chemical used to construct a calibration curve (internal standard concentrations kept 
constant). The linear regression from the calibration curve was observed in the form 
y=mx+b, where y represents the peak area ratio (test chemical/internal standard), x 
represents the concentration of the test chemical, and m represents the slope. The linear 
regression was used to determine the concentration of the test chemical as a function of 
the relative peak area ratio of the test chemical to the internal standard by rearranging 
the equation and solving for x.  
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2.6 Extraction Efficiency Tests 
For pyrene, benzo(a)pyrene, beta-HCH, and methoxychlor, extraction efficiency 
experiments were carried out to determine whether the chemical has an extraction 
efficiency >70% after being extracted from the incubation mixture into the extraction 
solvent. Two scintillation vials were prepared, consisting of phosphate buffer, HI-S9, and 
the test chemical (total volume of 4000μL). The S9 protein concentration for both vials 
was 1mg/mL. The mixture was vortexed for ten seconds, followed by transferring 
subsamples (n=3) of the mixture into clean 2mL autosampler vials containing 300μL ice 
cold acetonitrile. 1 mL of hexane was added to each vial and the vials were then 
vortexed for 10 minutes at 2400 rpm (SIP Ⓡ vortex mixer, Baxter Scientific Products, 
USA), followed by a 20-minute centrifugation (Centra CL2 benchtop centrifuge, Thermo 
IEC, USA) at 3000 rpm. Exactly 500 μL of this supernatant (hexane) was transferred to 
new 2 mL amber autosampler vials and the internal standard was added to all the vials. 
There were two more scintillation vials prepared by adding hexane and the test chemical 
(total volume of 4000μL). The mixture was vortexed, and subsamples of the mixture 
were transferred into clean 2mL autosampler vials (n=3) containing hexane, followed by 
adding the internal standard to all the vials. These vials serve to represent 100% 
extraction efficiency. For both the HIS9 and hexane vial, the ratio of the test chemical to 
internal standard ratio was obtained. Then the ratio for the HIS9 vial was divided by the 
ratio obtained for the hexane vial and multiplied by 100 to obtain the extraction 
efficiency.  
2.7 Protein Content Determination 
The protein content of the S9 subcellular fraction was determined by Yung Shan 
Lee using the Bradford protein assay (Bradford, 1976). A standard curve was generated 
using bovine serum albumin (Sigma-Aldrich) at concentrations of 0, 10, 20, 40, 60, 
80μg/mL. The BSA standard working solutions were prepared in Eppendorf tubes 
containing BSA and phosphate buffer (0.1 M, pH 7.4) to a final volume of 500μL. 
Subsequently, 50μL of each standard was pipetted into a 96 well plate with 200μL of 
diluted Bradford reagent (diluted 1/5 in deionized water) in triplicate (n=3). The S9 was 
also diluted in Eppendorf tubes containing the S9 and phosphate buffer. There were 
three batches of S9 and for each batch, the S9 was obtained from 3 different rats, 
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resulting in a total of 9 livers from which the S9 was obtained from. 50μL of the diluted 
S9 obtained from each batch was transferred to a 96 well plate with 200μL of diluted 
Bradford reagent with five replicates (n=5). Absorbance values of the BSA standards 
and liver S9 samples at a wavelength of 595 nm were determined using a Pharmacia 
LKB Ultrospec III UV/Vis spectrophotometer (Creve, Coeur, MO, USA). The mean 
protein concentration of each S9 sample was determined using the equation of the line 
from the standard curve, and then adjusted using the dilution factor (Bradford, 1976). 
2.8 Data and Statistical Analysis 
The solvent phase dosing method assumes first order depletion kinetics as 
shown in the equation:  
𝑑𝐶/𝑑𝑡 = −𝑘𝑑𝑒𝑝 ∗ 𝐶                                                                                            (2.1) 
where dC/dt is the change in concentration per unit time (μM/min), kdep is the first 
order depletion rate constant (1/min), and C is the starting substrate concentration (μM). 
The rate of depletion for all test chemicals was measured over time after the incubation. 
The natural logarithm of the substrate concentration in the active S9 and heat inactivated 
S9 was plotted over time and a slope was obtained with the following equation:   
𝑙𝑛𝐶 = −𝑘𝑑𝑒𝑝 ∗ 𝑡 + 𝑙𝑛𝐶𝑜                                                                                      (2.2) 
where C is the concentration (μM) of the test chemical at time t (min), and Co is 
the starting concentration (μM). The in vitro biotransformation rate constant (kr) was 
calculated using the equation:  
𝑘𝑟 = 𝑘𝑑𝑒𝑝,𝑡𝑒𝑠𝑡 − 𝑘𝑑𝑒𝑝,𝑐𝑡𝑟𝑙                                                                                    (2.3) 
where kdep,test is the first order depletion rate constant for the test chemical in the 
active S9 and the kdep,ctrl  is the first order depletion rate constant for the inactivated S9. 
For all chemicals in the negative control vials, simple linear regression analysis was 
conducted to determine whether the depletion rate in the HI-S9 vials was significantly 
different from 0. Simple linear regression analysis was completed using Excel. Multiple 
linear regression analysis was conducted to determine whether there was a significant 
difference between the depletion rates observed in the active S9 and the inactive S9 for 
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all test chemicals (including the positive control). Multiple linear regression analysis was 
completed with JMP 16. For the positive control, the mean kr values for pyrene from all 
five incubation experiments were compared using a one way analysis of variance 
(ANOVA). All other statistical analyses were completed with JMP 16.  
2.9 Modelling  
The whole organism biotransformation rate constants or the kmet values (1/h) 
were calculated using the IVIVE models developed by Lee et al. (2017), Nichols et al. 
(2013), and Krause & Goss (2018). Krause & Goss (2018) developed two models that 
were both used in this study to estimate the kmet value. The first model takes the blood 
flow into account and the second model is used to calculate the kmet value without taking 
the blood flow into consideration. The Kow value for all the IVIVE models were 
temperature corrected using the following equation:  









                                                      (2.4) 
where logKow(T) is the logKow value at temperature T, logKow(T0) is the logKow 
value at a reference temperature, ΔHow is the enthalpy of phase change (in kJ/mol), and 
R is the universal gas constant (in kJ/mol*K) (Beyer et al., 2002). In addition to the IVIVE 
models, a QSAR model developed by Arnott et al. (2014) and four QSAR models 
developed by Papa et al (2018) were used to estimate the whole organism 
biotransformation rate constant in humans (no QSAR model is currently developed for 
rats). The modelled results were compared to the in-vivo elimination rate constants or ke, 
obtained from the literature. 
2.9.1 IVIVE Models 
2.9.1.1 IVIVE-ph Model 
The IVIVE-pharmaceutical model by Nichols et al (2013) is a model that uses the 
hepatic clearance (CLH) and volume of distribution (Vd) to predict the whole organism 
biotransformation rate constant (kmet). First, the in-vitro biotransformation rate constant 
and the protein concentration in the S9 is used to estimate the in-vitro intrinsic clearance 





                                                                                                     (2.5) 
where kr is the in-vitro biotransformation rate constant and CP,inc is the 
concentration of protein in the S9. Next, the hepatic intrinsic clearance or the CLint,H (mL 
h-1 g organism-1) is calculated using the following equation: 
 𝐶𝐿𝑖𝑛𝑡,𝐻 = 𝐶𝐿𝑖𝑛𝑡 ∗ 𝐶𝑃,𝐻 ∗ ϕ𝐻,𝑤/𝑤                                                                         (2.6) 
where CLint is the intrinsic clearance (mL h-1 mg protein-1), CP,H is the S9 protein 
content in the liver (mg S9 protein/g liver), and ϕH, w/w is the fraction of liver in the 
organism (g liver/g organism). Next, the hepatic clearance is calculated based on a well 
stirred liver model obtained from Wilkinson and Shand (1975) (Nichlols et al, 2013). It is 
a function of hepatic flood flow similar to pharmaceutical methods. To estimate the blood 
flow, parameters like cardiac output and fraction of blood flow through the liver are 




                                                                                            (2.7) 
where CLH is the hepatic clearance (mL h-1 g organism-1), QH is the hepatic blood 
flow (mL blood h-1 g organism-1), CLint,H is the hepatic intrinsic clearance (mL h-1 g 
organism-1), and fu is the free fraction correction factor (unitless) which is calculated by 
dividing the unbound fraction of chemical in blood (fu.Bl) by the unbound fraction of the 
chemical in the incubation media (fu,inc). Finally, in order to calculate the whole organism 




                                                                                                        (2.8) 
Details on how to calculate the Vd can be found in Lee et al, (2017) and full 
details of the IVIVE-ph model can be found in Nichols et al (2013) and Lee et al. (2017). 
Model parameters are provided in Table E.5 of the appendix. 
2.9.1.2 IVIVE-b Model 
This IVIVE-bioaccumulation model was proposed by Lee et al (2017) and blood 
flow is not taken into account for the two following reasons: 1) chemicals that are 
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hydrophobic have low hepatic extraction ratios and their removal by the liver is not 
significantly affected by blood flow, 2) dietary uptake (of hydrophobic organic chemicals 
of limited volatility) is the major route of exposure for mammals. After an oral exposure, 
chemicals enter the liver via the hepatic portal vein and into the liver. In this case, the 
blood flow is not the rate determining step, the extraction of the unbound chemical is 
dependant on enzyme activity in the liver (Lee et al., 2017). Therefore, parameters like 
the cardiac output and fraction of blood flow through the liver (parameters that may not 
be readily available) are not required. This IVIVE approach is simplified and suited for 
bioaccumulation assessment of very hydrophobic chemicals. One major assumption of 
this method is that the liver is the main site of biotransformation in the body. First, the 
maximum in-vitro biotransformation rate constant or the k*r (1/h) is calculated as shown 
in the equation below: 




                                                                                                       (2.9) 
where kr, C->0 is the in-vitro biotransformation rate constant at an infinitesimally low 
concentration (1/h), and fu,inc is the unbound fraction of the chemical in the incubation 
mixture (unitless). Then the hepatic biotransformation rate constant is calculated 
according to the equation below: 
 𝑘𝑚𝑒𝑡,𝐻 = 𝑘  𝑟
∗ ∗ 𝑆𝐹 ∗ 𝑓𝑢,𝐻                                                                                   (2.10) 
where kmet,H is the hepatic biotransformation rate constant (1/h), k*r is the 
maximum in-vitro biotransformation rate constant (1/h), SF is the scaling factor 
(unitless), and fu,H is the unbound fraction of the chemical in the liver (unitless). This is 
followed by the estimation of the whole organism biotransformation rate constant 
according to: 
 𝑘𝑚𝑒𝑡 = 𝑘𝑚𝑒𝑡,𝐻 ∗
𝑀𝐻
𝑀𝐵
                                                                                         (2.11) 
where kmet is the whole organism biotransformation rate constant (1/h), kmet,H is 
the hepatic biotransformation rate constant (1/h), and MH/MB is the fraction of total 
chemical mass in the organism that is in the liver (unitless). Full details of the IVIVE-b 
model can be found in Lee et al (2017). All the model parameters and equations are 
found in Table E.4 of the appendix.  
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2.9.1.3 IVIVE-Krause & Goss Model (blood flow considered) 
The model was developed by Krause & Goss (2018) and it involves the 
extrapolation of the in-vitro biotransformation rate constant to the blood clearance to 
calculate the whole organism biotransformation rate constant. The model assumes that 
the organism is well stirred with an instantaneous sorption equilibrium. The in-vitro 





















                                                                    (2.12) 
where CLblood is the blood clearance (mL blood h-1 g organism-1), QH is the 
hepatic blood flow (mL blood h-1 g organism-1), fu,Bl is unbound fraction of the chemical in 
the blood (unitless), fU,inc is unbound fraction of the chemical in the incubation mixture 
(unitless), kr is the in-vitro biotransformation rate constant (1/h), CP,B is the S9 protein 
content of the organism (mg S9 protein g-1 organism-1), CP,inc is the protein concentration 
in the incubation mixture (mg protein/mL incubation mixture), fW,inc is the water fraction of 
the incubation mixture (mL water/mL incubation mixture), fW,Bl is the water fraction of the 
blood (mL water/mLblood). Then the blood clearance is used to calculate the whole 
organism biotransformation rate constant using the following equation: 
𝑘𝑚𝑒𝑡 = 𝐶𝐿𝑏𝑙𝑜𝑜𝑑 ∗  
𝑘𝑏𝑙𝑜𝑜𝑑/𝑤𝑎𝑡𝑒𝑟
𝑘𝑏𝑜𝑑𝑦/𝑤𝑎𝑡𝑒𝑟
                                                                            (2.13) 
where the kmet is the whole organism biotransformation rate constant (1/h), CLblood 
is the blood clearance (mL blood h-1 g organism-1), kblood/water is the blood-water partition 
coefficient (mL water/mL blood), and kbody/water is the body-water partition coefficient (mL 
water/mL organism). Full details of this model can be found in Krause & Goss (2018). 
Model parameters are provided in Table E.7 of the appendix. 
2.9.1.4 IVIVE-Krause & Goss Model (blood flow not considered) 
This model was also developed by Krause & Goss (2018) and the blood flow is 
not taken into account, meaning that the whole organism biotransformation rate constant 
can be calculated without blood clearance. Parameters like the cardiac output and 
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fraction of blood flow through the liver (parameters that may not be readily available) are 
not required. The whole organism biotransformation rate constant or the kmet (1/h) can be 
calculated using the following equation: 






                                                                         (2.13) 
where Cp,inc is the protein concentration in the incubation medium (mg protein/mL 
incubation mixture), CP,B is the S9 protein content of the organism (mg S9 protein/g 
organism), kblood/water is the blood-water partition coefficient (mL water/mL blood), and 
kbody/water is the body-water partition coefficient (mL water/mL organism). Model 
parameters are provided in Table E.6 of the appendix. 
2.9.2 QSAR Models 
The Quantitative Structure Activity Relationships (QSAR) model is an in-silico 
model that uses the chemical structure of a compound to predict various parameters. 
Currently in the field of environmental science, there are only five QSAR models 
available to predict the biotransformation rate constant for humans (no QSAR model 
currently available for rats). There is a QSAR model developed by Arnott et al (2014), 
(which will be referred to as the QSAR a1 model in this study) and four QSAR models 
developed by Papa et al. (2018) (QSAR b1, b2, b3, and b4 models) that were used in 
this study to predict the whole organism biotransformation rate constants for humans.  
2.9.3 Model Performance Analysis 
All the models were compared quantitatively using various statistical parameters. 
The average IVIVE model outputs and single QSAR outputs for each model were plotted 
against the average elimination rate constants from the in-vivo data (for each test 
chemical). Simple linear regression analysis was conducted to obtain various statistical 
parameters. One of the parameters used to compare the models was the coefficient of 
determination (R2), which is used for judging the goodness of fit in a linear regression 
model (Cheng & Garg, 2014). A higher R2 value indicates a better fit of the regression 
model with the observed data. Another parameter used to compare the models was the 
probability value (p-value) of the slope which is a number that describes the probability 
of the null hypothesis being true. A lower p-value of the slope indicates a greater 
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confidence that the predicted and observed values are correlated in a linear fashion. The 
slope and the slope error for the linear regressions was also used to compare the 
models. The slope error relative to the slope was calculated by dividing the slope error 
by the slope. Next, the models were compared using the root mean square error 
(RMSE) which is used to measure the error of the model. A higher RMSE indicates that 
the model has a higher degree of error. Another parameter used to compare the models 
was the model bias which is used to measure the systematic overprediction (MB>1) and 
underprediction (MB<1) of a model (Gobas & Arnott, 2009). The model bias will track the 
central tendency of the ability of the model to make predictions. In addition to the model 
bias, the upper and lower standard deviations (SD) for the model bias were also used to 
determine the error associated with all the models. When the model bias has a 
numerical value close to 1 and a low error (small distance between upper and lower SD), 
this indicates that the model performs very well (Gobas & Arnott, 2009).  
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3 Results and Discussion 
3.1  Calibration Curves 
For all the test chemicals (including pyrene), the calibration curves are displayed 
in Appendix A. There were 6 calibration curves generated in total (3 for the test chemical 
and 3 for the pyrene positive control). The calibration curve for each test chemical shows 
the relationship between the peak area ratio (test chemical/internal standard) and 
concentration of test chemical which can be used to estimate unknown concentration for 
each experiment.  
3.2  Protein Content Determination  
The average mean protein S9 concentrations for the batch 1, batch 2, and batch 
3 were 54.1 ± 1.1, 66.2 ± 1.8, and 62.0 ± 1.1 mg protein/mL S9 (mean ± standard 
deviation, n=3). The BSA standard curve is displayed in Appendix B and the linear 
regression has a trendline with an R2 value of 0.9771 and an equation of y=0.0073x + 
0.0526, where y represents the blank subtracted absorbance value (with a standard 
error of 0.0236) and x represents the BSA concentration (with a standard error of 
0.000479). The linear regression has a p-value of 0.000440. The equation obtained from 
the linear regression was used to convert the blank subtracted absorbance values into 
concentration values that are multiplied by the dilution factor (1500) to get overall 
concentration values that are displayed in Table B-1 of the appendix. The average 
protein concentrations of each replicate for each batch of S9 are displayed in Table B-2. 
A statistically significant difference in protein concentration was observed between all 3 
batches of S9, indicating intraspecies variation between the rats used in this study.  
3.3 Preliminary Experiments 
The depletion rates for each test chemical at different concentrations can be 
found in Figures 3.1 to 3.5. The detection limits for each test chemical in the incubation 
mixture was 0.025 µM for benzo(a)pyrene, 0.25 µM for beta-HCH, 0.5 µM for 
methoxychlor, 0.5 µM for mono-n-butyl phthalate, and 1 µM for 4-n-nonylphenol (Table 
D.1 of the appendix). A slow depletion rate was observed for beta-HCH, hence longer 
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incubation times were used. The time points for each test chemical are shown in Table 
D.1 of the appendix.  
 
 
Figure 3.1. Natural logarithm of the concentration (µM) of benzo(a)pyrene in rat 
liver S9 subcellular fractions as a function of time (min), illustrating 
the depletion of benzo(a)pyrene (test chemical) at different initial 
concentrations in the incubation medium during the preliminary 
experiments. 
P – P-values  
N – number of replicates 
Linear regression equation includes standard error of slope in parenthesis 
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Figure 3.2. Natural logarithm of the concentration (µM) of beta-HCH in rat liver 
S9 subcellular fractions as a function of time (min), illustrating the 
depletion of beta-HCH (test chemical) at different initial 
concentrations in the incubation medium during the preliminary 
experiments. 
P – P-values  
N – number of replicates 




Figure 3.3. Natural logarithm of the concentration (µM) of methoxychlor in rat 
liver S9 subcellular fractions as a function of time (min), illustrating 
the depletion of methoxychlor (test chemical) at different initial 
concentrations in the incubation medium during the preliminary 
experiments. 
P – P-values  
N – number of replicates 




Figure 3.4. Natural logarithm of the concentration (µM) of mono-n-butyl 
phthalate in rat liver S9 subcellular fractions as a function of time 
(min), illustrating the depletion of mono-n-butyl phthalate (test 
chemical) at different initial concentrations in the incubation 
medium during the preliminary experiments. 
P – P-values  
N – number of replicates 




Figure 3.5. Natural logarithm of the concentration (µM) of 4-nonylphenol in rat 
liver S9 subcellular fractions as a function of time (min), illustrating 
the depletion of 4-nonylphenol (test chemical) at different initial 
concentrations in the incubation medium during the preliminary 
experiments. 
P – P-values  
N – number of replicates 
Linear regression equation includes standard error of slope in parenthesis 
 
3.4 Final Experiments 
The decline of chemical concentration over time obtained from the in-vitro 
substrate depletion experiments can be found in Figures 3.7 to 3.21. 
3.4.1 Negative Controls 
Using simple linear regression, slopes were obtained for all test chemicals in the 
inactive S9 to determine whether there was significant depletion. It was found that the 
depletion rate constants for benzo(a)pyrene, methoxychlor, mono-n-butyl phthalate, and 
4-n-nonylphenol were not significantly different from 0 (p>0.05), indicating no significant 
loss. However, for beta-HCH, all three batches indicated a depletion rate significantly 
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different from 0. For all pyrene incubations in the inactive S9, that were run alongside 
benzo(a)pyrene, methoxychlor, mono-n-butyl phthalate, and 4-n-nonylphenol, the 
depletion was not significantly different from 0 (p>0.05). However, for the pyrene 
incubations run alongside beta-HCH, the depletion was significantly different from 0 for 
batches 1 and 2. A possible explanation for why the depletion rates were significantly 
different from 0 for beta-HCH and the pyrene run alongside beta-HCH may be due to the 
incubation being 90 minutes long for both chemicals in the inactive S9 vial (Figures 3.10 
to 3.12). This causes evaporation to take place for a long period of time, resulting in a 
significant loss of mass for both chemicals. Hence, lowering the concentration in the 
incubation mixture (with time), which will cause the depletion rate to be significantly 
different from 0. However, the purpose of the negative control is to control for these 
additional factors that may affect the experiment. For example, evaporation of chemicals 
in the incubation mixture will occur for both the active and inactive S9 vials during long 
incubations. Therefore, the loss of chemical through evaporation is controlled for when 
calculating the biotransformation rate constant (kr). 
3.4.2 Test Chemicals  
Using multiple linear regression, it was determined whether depletion rates of 
test chemicals in active S9 were significantly different from the depletion rates of the test 
chemicals in the inactive S9. The p-values obtained from multiple linear regression are 
displayed in Table D.2 of the appendix. The depletion rates for benzo(a)pyrene, 
methoxychlor, mono-n-butyl phthalate, and 4-n-nonylphenol in active S9 were 
significantly different from the depletion rate observed in the inactive S9. However, beta-
HCH had depletion rates in the active S9 that were significantly different from the 
depletion rates in the inactive S9 for batches 1 and 3, indicating depletion could not be 
confirmed in batch 2. The mean biotransformation rate constants (kr) for 
benzo(a)pyrene, beta-HCH, methoxychlor, mono-n-butyl phthalate, and 4-n-nonylphenol 
were determined to be 0.193 ± 0.0270, 0.0012 ± 0.000702, 0.46 ± 0.0368, 0.042 ± 
0.00732, and 0.0716 ± 0.00589 min-1 (mean ± standard error of mean), respectively.  
3.4.3 Positive Control 
One way analysis of variance (ANOVA) was used to determine whether there is 
a significant difference between the mean kr values (n=3) from the five pyrene incubation 
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experiments that were run in parallel with the incubation experiments for each test 
chemical. No statistically significant differences were observed (p=0.0607) between the 
mean kr values.  
The p-values obtained from multiple linear regression for the pyrene incubations 
that were run in parallel with the incubation experiments for the test chemicals are 
displayed in Table D.3 of the appendix. For all pyrene incubations that were run in 
parallel with all the test chemicals, the depletion rates for the active S9 were significantly 
different from the depletion rate observed in the inactive S9 (p<0.0001). This indicates 
that for all incubation experiments and all batches, biotransformation of the test 
chemicals took place. The mean kr values from the pyrene incubation experiments (n=3) 
conducted in parallel with benzo(a)pyrene, beta-HCH, methoxychlor, mono-n-butyl 
phthalate, and 4-n-nonylphenol were 0.244 ± 0.0141, 0.289 ± 0.0276, 0.195 ± 0.0255, 
0.269 ± 0.0181, and 0.228 ± 0.0104 min-1 (mean ± standard error of mean), respectively. 
Even though there is slight variation observed, the difference it not statistically 
significant. The mean kr values from the pyrene incubation experiments are displayed in 
Figure 3.6. The pyrene experiments that were run in parallel with methoxychlor had the 
highest variance and pyrene experiments that were run in parallel with 4-n-nonylphenol 
had the lowest variance. The mean pyrene kr from all the incubation experiments was 
0.245 ± 0.0116 min-1 (mean ± standard error of the mean). 
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Figure 3.6. Mean of in-vitro biotransformation rate constants (n=3) from the 
pyrene incubation experiments that were run in parallel with the 
incubations for all test chemicals (mean ± standard error of mean). 
Coeffiecient of variance (CV) values are displayed to show the 
variability observed for the different incubation experiments.  
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Figure 3.7. Final experiment using the active rat liver S9 fraction from batch 1 to 
determine the first order depletion rate constants for benzo(a)pyrene 
(test chemical) and pyrene (reference chemical). The 
ln(concentration) values are plotted against time and the slope is 
obtained for both the active S9 and the heat inactivated S9 (HIS9). 
The difference between the slopes is the in vitro depletion rate 
constant.   
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Figure 3.8. Final experiment using the active rat liver S9 fraction from batch 2 to 
determine the first order depletion rate constants for benzo(a)pyrene 
(test chemical) and pyrene (reference chemical). The 
ln(concentration) values are plotted against time and the slope is 
obtained for both the active S9 and the heat inactivated S9 (HIS9). 
The difference between the slopes is the in vitro depletion rate 
constant.   
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Figure 3.9. Final experiment using the active rat liver S9 fraction from batch 3 to 
determine the first order depletion rate constants for benzo(a)pyrene 
(test chemical) and pyrene (reference chemical). The 
ln(concentration) values are plotted against time and the slope is 
obtained for both the active S9 and the heat inactivated S9 (HIS9). 
The difference between the slopes is the in vitro depletion rate 
constant.   
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Figure 3.10. Final experiment using the active rat liver S9 fraction from batch 1 to 
determine the first order depletion rate constants for beta-HCH (test 
chemical) and pyrene (reference chemical). The ln(concentration) 
values are plotted against time and the slope is obtained for both the 
active S9 and the heat inactivated S9 (HIS9). The difference between 
the slopes is the in vitro depletion rate constant.   
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Figure 3.11. Final experiment using the active rat liver S9 fraction from batch 2 to 
determine the first order depletion rate constants for beta-HCH (test 
chemical) and pyrene (reference chemical). The ln(concentration) 
values are plotted against time and the slope is obtained for both the 
active S9 and the heat inactivated S9 (HIS9). The difference between 
the slopes is the in vitro depletion rate constant.   
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Figure 3.12. Final experiment using the active rat liver S9 fraction from batch 3 to 
determine the first order depletion rate constants for beta-HCH (test 
chemical) and pyrene (reference chemical). The ln(concentration) 
values are plotted against time and the slope is obtained for both the 
active S9 and the heat inactivated S9 (HIS9). The difference between 
the slopes is the in vitro depletion rate constant.   
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Figure 3.13. Final experiment using the active rat liver S9 fraction from batch 1 to 
determine the first order depletion rate constants for methoxychlor 
(test chemical) and pyrene (reference chemical). The 
ln(concentration) values are plotted against time and the slope is 
obtained for both the active S9 and the heat inactivated S9 (HIS9). 
The difference between the slopes is the in vitro depletion rate 
constant.   
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Figure 3.14. Final experiment using the active rat liver S9 fraction from batch 2 to 
determine the first order depletion rate constants for methoxychlor 
(test chemical) and pyrene (reference chemical). The 
ln(concentration) values are plotted against time and the slope is 
obtained for both the active S9 and the heat inactivated S9 (HIS9). 
The difference between the slopes is the in vitro depletion rate 
constant.   
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Figure 3.15. Final experiment using the active rat liver S9 fraction from batch 3 to 
determine the first order depletion rate constants for methoxychlor 
(test chemical) and pyrene (reference chemical). The 
ln(concentration) values are plotted against time and the slope is 
obtained for both the active S9 and the heat inactivated S9 (HIS9). 
The difference between the slopes is the in vitro depletion rate 
constant.   
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Figure 3.16. Final experiment using the active rat liver S9 fraction from batch 1 to 
determine the first order depletion rate constants for mono-n-butyl 
phthalate (test chemical) and pyrene (reference chemical). The 
ln(concentration) values are plotted against time and the slope is 
obtained for both the active S9 and the heat inactivated S9 (HIS9). 
The difference between the slopes is the in vitro depletion rate 
constant.   
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Figure 3.17. Final experiment using the active rat liver S9 fraction from batch 2 to 
determine the first order depletion rate constants for mono-n-butyl 
phthalate (test chemical) and pyrene (reference chemical). The 
ln(concentration) values are plotted against time and the slope is 
obtained for both the active S9 and the heat inactivated S9 (HIS9). 
The difference between the slopes is the in vitro depletion rate 
constant.   
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Figure 3.18. Final experiment using the active rat liver S9 fraction from batch 3 to 
determine the first order depletion rate constants for mono-n-butyl 
phthalate (test chemical) and pyrene (reference chemical). The 
ln(concentration) values are plotted against time and the slope is 
obtained for both the active S9 and the heat inactivated S9 (HIS9). 
The difference between the slopes is the in vitro depletion rate 
constant.   
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Figure 3.19. Final experiment using the active rat liver S9 fraction from batch 1 to 
determine the first order depletion rate constants for 4-n-
nonylphenol (test chemical) and pyrene (reference chemical). The 
ln(concentration) values are plotted against time and the slope is 
obtained for both the active S9 and the heat inactivated S9 (HIS9). 
The difference between the slopes is the in vitro depletion rate 
constant.   
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Figure 3.20. Final experiment using the active rat liver S9 fraction from batch 2 to 
determine the first order depletion rate constants for 4-n-
nonylphenol (test chemical) and pyrene (reference chemical). The 
ln(concentration) values are plotted against time and the slope is 
obtained for both the active S9 and the heat inactivated S9 (HIS9). 
The difference between the slopes is the in vitro depletion rate 
constant.   
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Figure 3.21. Final experiment using the active rat liver S9 fraction from batch 2 to 
determine the first order depletion rate constants for 4-n-
nonylphenol (test chemical) and pyrene (reference chemical). The 
ln(concentration) values are plotted against time and the slope is 
obtained for both the active S9 and the heat inactivated S9 (HIS9). 
The difference between the slopes is the in vitro depletion rate 
constant.   
3.5 IVIVE 
A comparison between the whole organism biotransformation rate constants 
obtained from the four IVIVE models, biotransformation rate constants obtained from the 
five QSAR models, and elimination rate constants obtained from in-vivo studies can be 
found in Figures 3.23 to 3.28. The numerical values for all the model outputs can be 
found in Tables E.8 and E.9 of the appendix. Each model calculated the kmet value, 
which is the total biotransformation that takes place within an organism. The kmet value is 
the fraction of chemical that is metabolized in an organism per unit time. The ke value 
refers to the elimination rate constant which is the fraction of chemical eliminated from 
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an organism per unit time, and it includes both metabolism and excretion of the parent 
compound. The ke value from various studies for pyrene, benzo(a)pyrene, beta-HCH, 
mono-n-butyl phthalate, and 4-n-nonylphenol can be found in Table F.1 of the appendix.  
3.5.1 kmet/kr Ratios 
The ratio of the kmet and kr value was used to compare the whole organism 
biotransformation rate constants to the in-vitro biotransformation rate constants for all 
test chemicals (Figure 3.22). The kmet/kr values for the IVIVE-b model are displayed in 
Figure 3.22a. The findings indicate that an increase in the Kow value results in a 
decrease in the whole organism biotransformation rate constant (compared to the in vitro 
biotransformation rate constant), until it plateaus (Figure 3.22a). This pattern is observed 
due to the lipid and protein content in the liver. As the Kow increases, more chemical is 
bound to the lipids and proteins, resulting in a lower unbound fraction (less chemical will 
be bioavailable to react with the enzymes) (Lee et al, 2017). For the IVIVE-b model, the 
whole organism biotransformation rate constant kmet (1/h) is dependant on the unbound 
fraction of the chemical in the liver fu,H as shown in Table. E.4 of the appendix. As the 
Kow value increases, the fu,H decreases until it plateaus. Hence, this will cause the kmet 
value to decrease with an increase in the Kow value, until it plateaus, as shown in Figure 
3.22a. 
The kmet/kr values for the IVIVE-ph model are displayed in Figure 3.22b. A similar 
pattern is observed where the kmet/kr ratio exponentially decreases with the Kow value 
until it plateaus (Figure 3.22b). The kmet value for the IVIVE-ph model is dependant on 
both the hepatic clearance CLH and volume of distribution Vd, as shown in Table E.5 of 
the appendix. The Vd is related to the total amount of drug in the body to the plasma 
concentration of the drug at a given time (Mansoor & Mahabadi, 2020). A low Vd 
indicates that most of the chemical remains in the plasma. A high Vd indicates that most 
of the chemical ends up in extravascular tissue compartments of the body (Mansoor & 
Mahabadi, 2020). Hence, a high Vd will result in less chemical in the blood being 
bioavailable for biotransformation. The Vd is a parameter that exponentially increases 
with an increase in the Kow value, until it plateaus. Thereby, resulting in the kmet value 
exponentially decreasing as the Kow increases, as shown in Figure 3.22b.  
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 For both IVIVE Krause and Goss models, the kmet/kr ratios are displayed in 
Figure 3.22c and Figure 3.22d. The kmet/kr ratios are also shown to exponentially 
decrease with the Kow value, until reaching a plateau phase. The kmet values for the 
IVIVE Krause and Goss models (blood flow not considered) are dependant on the body-
water partition coefficient kbody/water, as shown in Table E.6 and Table E.7 of the appendix. 
The kbody/water value is the denominator for both equations from both models that are used 
to calculate the kmet value. The kbody/water exponentially increases with the Kow value until it 
plateaus. Hence, the kmet value will exponentially decrease with an increase in the Kow 
value, until it plateaus.  
Overall, all four IVIVE models generate outputs that are highly dependant on the 
Kow value. After the in-vitro biotransformation is calculated, the chemicals Kow value plays 
a vital role in determining how large the kmet value will be relative to the kr value. 
3.5.2 Comparison between Model Outputs and In-Vivo Elimination 
Rate Constants 
The kmet values from the IVIVE models were compared to one another to 
determine whether there was variation observed between the model outputs. The 
findings indicate that the model outputs were fairly similar to one another. The overall 
difference between each IVIVE model for all the test chemicals was less than 1.7-fold 
(Table E.8 of the appendix). The kmet values obtained from all the IVIVE models were 
also compared to the in-vivo data for each test chemical. Since there was no in-vivo data 
available for methoxychlor, it was excluded from the analysis. The mean whole organism 
biotransformation rate constants for the IVIVE models and the mean elimination rate 
constants ke from the in-vivo data are shown in Figures 3.23 to 3.28. For mono-n-butyl 
phthalate, the model outputs for all the IVIVE models are shown in Table E.8 of the 
appendix. The mean model outputs for mono-n-butyl phthalate from the IVIVE-b, IVIVE-
ph, IVIVE-Krause & Goss (blood flow considered), and IVIVE-Krause & Goss (blood flow 
not considered) model were greater than the mean ke value (0.241 ± 0.0361 (mean ± 
SE)) by a factor of 1.14, 1.14, 1.48, and 1, respectively. The findings indicate that the 
model outputs are very similar to the elimination rate constants from the in-vivo data, 
indicating that the models do a great job making predictions for this chemical. Sprague-
Dawley rats were used for all the in-vivo experiments conducted for mono-n-butyl 
phthalate (Table F.1 of the appendix). For this study, the in vitro experiments were also 
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conducted using liver from male Sprague-Dawley rats. Using the same rat strain for this 
study and for the in-vivo studies may account for why the prediction accuracy was high 
for mono-n-butyl phthalate. Additionally, mono-n-butyl phthalate may primarily be 
metabolized in the liver (extrahepatic biotransformation is negligible) because 
extrahepatic metabolism results in a lower kmet value in comparison to the in-vivo ke 
values. 
For benzo(a)pyrene, beta-HCH, and 4-n-nonylphenol, the mean kmet values 
obtained from all the IVIVE models (Table E.8 of the appendix) were lower than the in-
vivo elimination rate constants (Figures 3.24, 3.25, and 3.28). The mean ke value (0.420 
± 0.128 (mean ± SE)) for benzo(a)pyrene was greater than the mean kmet values from 
the IVIVE-b, IVIVE-ph, IVIVE-Krause & Goss (blood flow considered), and IVIVE-Krause 
& Goss (blood flow not considered) model by a factor of 3.79, 4.07, 2.93, and 3.56, 
respectively. The mean ke value (0.00649 ± 0.00381 (mean ± SE)) for beta-HCH was 
greater than the mean kmet values from the IVIVE-b, IVIVE-ph, IVIVE-Krause & Goss 
(blood flow considered), and IVIVE-Krause & Goss (blood flow not considered) model by 
a factor of 4.29, 3.80, 3.31, and 3.33, respectively. And finally, the mean ke value (0.104 
± 0.0236 (mean ± SE)) for 4-n-nonylphenol was greater than the mean kmet values from 
the IVIVE-b, IVIVE-ph, IVIVE-Krause & Goss (blood flow considered), and IVIVE-Krause 
& Goss (blood flow not considered) model by a factor of 2.57, 2.49, 1.98, and 2.14, 
respectively. The in-vivo studies are expected to have higher elimination rate constant 
values than the model outputs obtained from the IVIVE models due to biotransformation 
that may take place outside the liver and other routes of elimination. For this study, a 
limitation specific to the IVIVE models is that it assumes the main site for 
biotransformation is the liver. This creates uncertainty because extrahepatic metabolism 
is not taken into consideration. The intestine (and the content it contains) is also known 
to contribute to first pass metabolism for chemicals that enter the bloodstream via the 
diet (Ramesh et al., 2004). Biotransforming enzymes that are found in the liver could be 
found in extrahepatic organs as well. For example, it was shown in humans that high 
amounts of CYP3A4 is found in both the liver and the intestine (Krishna & Ulrich, 1994). 
For phase II metabolism, it was shown that Glutathione S-Transferases is found in both 
the liver and gastrointestinal tract (in its neutral form) (Krishna & Ulrich, 1994).  
The IVIVE model outputs for pyrene (Table E.8 of the appendix) had values that 
were greater than the elimination rate constants obtained from in-the vivo studies. The 
57 
mean ke value (0.0609 ± 0.00727 (mean ± SE)) for pyrene was greater than the model 
outputs obtained from the IVIVE-b, IVIVE-ph, IVIVE-Krause & Goss (blood flow 
considered), and IVIVE-Krause & Goss (blood flow not considered) model by a factor of 
2.64, 2.31, 3.42, and 2.60, respectively. All the ke values for pyrene were obtained from 
a single study that exposed rats to pyrene at various doses. (Withey et al, 1991). A 
possible explanation for why the ke values were lower than the model outputs could be 
related to the different strain of rats being used. The study by Withey et al. (1991) used 
Wistar rats and it’s possible that this strain of rats could have less enzyme activity (for 
enzymes that metabolize pyrene) compared to the male Sprague-Dawley rats that were 
used in the in-vitro experiments for this study. Another explanation for why the ke values 
were lower than the model outputs could be related to the rat body weight. The rats used 
in the pyrene in-vivo studies weighed approximately 400g, which is much heavier than 
the rats that were used for in-vivo studies conducted for the remaining test chemicals. 
Essentially, as organisms get larger the half life gets longer, which results in a smaller 
elimination rate constant value (Arnot et al., 2009). The large body weight for the rats 
used in the pyrene in-vivo study could contribute to the low elimination rate constants 
that were observed. Additionally, the concentration of pyrene used in this study for the 
in-vitro experiments was very low and a lower concentration is associated with a higher 
biotransformation rate constant, as shown in the preliminary experiment (Figures 3.1 to 
3.5). This would explain the high kmet values obtained from the IVIVE models for pyrene.  
For all test chemicals, a common pattern observed was that the IVIVE-Krause & 
Goss (blood flow not considered) model was always shown to have the highest kmet 
value (compared to the other models). However, the kmet values from all the IVIVE 
models were overall very similar to one another for all test chemicals. There may be 
slight variation but the difference between the four IVIVE model outputs was less than 
1.7-fold. Since all four models were shown to compute similar model outputs, this 
indicates that all the IVIVE models could be used for bioaccumulation assessment. 
However, the advantage of the IVIVE-b model is that it requires fewer biological 
parameters compared to the IVIVE-ph and IVIVE-Krause & Goss (blood flow 
considered) models, therefore it could potentially be applied to species other than rats 
(Lee, 2016). This is also true for the IVIVE-Krause & Goss model (blood flow not 
considered). It is recommended that the IVIVE-b model and IVIVE-Krause & Goss model 
(blood flow not considered) be used for bioaccumulation assessment since simple 
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models are preferred over complex ones. For three of the test chemicals used in this 
study, the kmet values were lower than the ke values for all the IVIVE models, possibly 
due to extrahepatic biotransformation and other elimination routes. Hence, the IVIVE 
models should be further developed and incorporate other routes of biotransformation. 
3.5.3 QSAR Models 
For each test chemical, the whole organism biotransformation rate constants 
obtained from the QSAR models were compared to one another, and the model outputs 
are displayed in Table E.9 of the appendix. For each test chemical, the difference 
between the highest model output and lowest model output value from all five QSAR 
models was by a factor of >3 for most of the test chemicals, implying that there is more 
variability in the QSAR models than the IVIVE models. The highest amount of variation 
in the QSAR model outputs was observed for beta-HCH. For beta-HCH, the difference 
between the highest model output (QSAR B3) and lowest model output (QSAR B1) 
value was a factor of 8.  
The comparison of the QSAR model outputs and in-vivo elimination rate 
constants (Figures 3.23 to 3.28) for benzo(a)pyrene and beta-HCH showed that all 
QSAR model output values were lower than the in-vivo elimination rate constants (Table 
F.1 of the appendix). The mean in-vivo ke values for benzo(a)pyrene were greater than 
the QSAR a1, QSAR b1, QSAR b2, QSAR b3, and QSAR b4 models by a factor of 8.33, 
17.0, 4.55, 9.75, and 7.69, respectively. Additionally, the mean in-vivo ke values for beta-
HCH were greater than the QSAR a1, QSAR b1, QSAR b2, QSAR b3, and QSAR b4 
models by a factor of 28.32, 38.71, 29.14, 4.83, respectively. A limitation associated with 
the QSAR models is that all chemical classes are not represented in the QSAR training 
set, therefore the application of the QSAR models could be limited to certain chemicals 
(Lee, 2016). The large difference between the model outputs and in-vivo data may be a 
result of the QSAR model training sets not incorporating these chemicals or chemicals 
that have a similar chemical structure as benzo(a)pyrene and beta-HCH.  
The QSAR model outputs for mono-n-butyl phthalate, 4-n-nonylphenol, and 
pyrene, were much closer to the in-vivo ke values, compared to the benzo(a)pyrene and 
beta-HCH model outputs (as shown in Figure 3.23, 3.27, and 3.28). The mean ke value 
for mono-n-butyl phthalate was compared to the QSAR a1, QSAR b1, QSAR b2, QSAR 
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b3, and QSAR b4 model outputs, and the difference was a factor of 2.28, 1.18, 1.08, 
2.54, and 1.54, respectively. The QSAR b2 model output was the closest to the ke value, 
followed by the QSAR b1 and QSAR b4 model. When the mean ke value for 4-n-
nonylphenol was compared to the QSAR a1, QSAR b1, QSAR b2, QSAR b3, and QSAR 
b4 model outputs, the difference was a factor of 4.13, 1.21, 2.29, 5.59, and 3.04, 
respectively. This time the QSAR b1 model performed very well compared to the other 
QSAR models. When the mean ke value for pyrene was compared to the QSAR a1, 
QSAR b1, QSAR b2, QSAR b3, and QSAR b4 model outputs, the difference was a 
factor of 1.36, 1.30, 2.59, 1.27, and 1.57, respectively. A possible reason for why the 
QSAR model performs well for these test chemicals could be related to the model 
training sets that were used to calibrate the models. Even though pyrene, mono-n-butyl 
phthalate, and 4-n-nonylphenol were not included in the training sets, there may be 
chemicals with a similar chemical structure used to calibrate the models. 
Overall, the QSAR models perform very well for some of the test chemicals and 
performed poorly for others. If the model performs very poorly for a specific chemical, 
this may lead to mischaracterization of a chemical’s bioaccumulation potential. There 
was also variability observed between the QSAR models and this raises the question of 
which model should be used for bioaccumulation assessment. However, the QSAR 
models can still be further developed in the near future to improve the model 
performance.  
3.5.4 Model Performance Analysis 
The various metrics that were used to compare the performance of the IVIVE and 
QSAR models are displayed in Table 3.1. When the coefficient of determination (R2) was 
calculated for the IVIVE models, it was shown that all four IVIVE models had very similar 
R2 values, implying that the goodness of fit for the regression models with the observed 
data was very similar. For the QSAR models, the R2 values were very similar for the 
QSAR a1, QSAR b1, and QSAR b4 models. The QSAR b2 model had the highest R2 
value and the QSAR b3 model had the lowest R2 value out of the QSAR models. 
Overall, the R2 values obtained from the IVIVE models were higher than the values 
obtained from the QSAR models  
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The p-values of the slope obtained for all the IVIVE models were also similar to 
one another. For the QSAR models, the p-values were very similar for the QSAR a1 
model, QSAR b1 model, and QSAR b4 model. The QSAR b2 model had the lowest p-
value and the QSAR b3 model had the highest p-value out of all the QSAR models. 
Overall, the p-values from the IVIVE models were lower than the p-values obtained from 
the QSAR models. The R2 and P-values both indicate that there is some variation in 
model performance for the QSAR models, as the IVIVE models are more consistent in 
terms of performance.  
Next, the RMSE and slope error (relative to slope) values were compared for 
each model to determine the error associated with the model outputs. The RMSE and 
slope error values obtained from the IVIVE models were quite similar. Additionally, the 
RMSE and slope error from the IVIVE models was lower compared to the QSAR 
models. For the QSAR models, the RMSE and slope error was highest for the QSAR b1 
model and the lowest for the QSAR b3 model. Lastly, the model bias with the standard 
deviation was another statistical parameter used to determine whether the model 
underpredicts or overpredicts the in-vivo ke. All the IVIVE models and QSAR models 
were not shown to underpredict or overpredict the in-vivo ke. In addition to the model 
bias, the standard deviation of the model bias was used to determine the error 
associated with the models. The error associated with IVIVE models was very similar 
and shown to be lower than the error that was calculated for the QSAR a1 model, QSAR 
b1 model, QSAR b3 model and QSAR b4 model. Additionally, the error for the IVIVE 
models was slightly lower than the error calculated for the QSAR b2 model.  
The overall trend for the chemicals tested in this study indicates that the IVIVE 
models perform better than most of the QSAR models. However, there were only 5 
chemicals tested and variability observed for the in-vivo data. Additionally, the QSAR 
models are developed for humans and the in-vivo data was collected from rat studies, 
which indicates that the QSAR model for humans may be of limited use in determining 
the in-vivo biotransformation rate constant in rats. It may be better to use QSAR model 
for determining the whole organism biotransformation rate constants in humans. In this 
study, the QSAR b2 model exceeded the other QSAR models in terms of performance. 
A possible explanation for this may be that the dataset used to calibrate the QSAR b2 
model may consist of chemicals that have a chemical structure that is more similar to the 
chemicals used in this study compared the other QSAR models.  
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Figure 3.22. The kmet/kr ratio for pyrene, benzo(a)pyrene, methoxychlor, mono-n-
butyl phthalate, and 4-n-nonylphenol for the (a) IVIVE-b model, (b) 
IVIVE-ph model, (c) IVIVE-Krause & Goss model (blood flow not 
considered), and the (d) IVIVE-Krause & Goss model (blood flow 
considered) as a function of the Kow value. The equation for the 
curve and R2 value is shown on the graph. For all four models, a 






Figure 3.23. Comparison of the whole organism biotransformation rate constants obtained for pyrene from the IVIVE and 
QSAR models, along with the total elimination rate constant obtained from in-vivo studies. Plots on the graph 
represent the average kmet values from the IVIVE models (n=3), the kmet values from the QSAR models, and 
average ke values from the in vivo data.  
aCalculated whole organism kmet using the IVIVE-B model 
bCalculated whole organism kmet using the IVIVE-Ph model 
cCalculated whole organism kmet using the IVIVE-Krause & Goss model I (blood flow limitation not considered) 
dCalculated whole organism kmet using the IVIVE-Krause & Goss model II (blood flow limitation considered) 
eCalculated human biotransformation rate constant using the QSAR model from Arnott et al. (2014) fCalculated human biotransformation rate 
constant using the QSAR model based on dataset 1 from Papa et al. (2018) 
gCalculated human biotransformation rate constant using the QSAR model based on dataset 2 from Papa et al. (2018) 
hCalculated human biotransformation rate constant using the QSAR model based on dataset 3 from Papa et al. (2018) 
iCalculated human biotransformation rate constant using the QSAR model based on dataset 4 from Papa et al. (2018) 
jTotal elimination rate constants (ke) from in vivo rodent database 
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Figure 3.24. Comparison of the whole organism biotransformation rate constants obtained for benzo(a)pyrene from the 
IVIVE and QSAR models, along with the total elimination rate constant obtained from in-vivo studies. Plots on 
the graph represent the average kmet values from the IVIVE models (n=3), the kmet values from the QSAR 
models, and average ke values from the in vivo data. 
aCalculated whole organism kmet using the IVIVE-B model 
bCalculated whole organism kmet using the IVIVE-Ph model 
cCalculated whole organism kmet using the IVIVE-Krause & Goss model I (blood flow limitation not considered) 
dCalculated whole organism kmet using the IVIVE-Krause & Goss model II (blood flow limitation considered) 
eCalculated human biotransformation rate constant using the QSAR model from Arnott et al. (2014) 
fCalculated human biotransformation rate constant using the QSAR model based on dataset 1 from Papa et al. (2018) 
gCalculated human biotransformation rate constant using the QSAR model based on dataset 2 from Papa et al. (2018) 
hCalculated human biotransformation rate constant using the QSAR model based on dataset 3 from Papa et al. (2018) 
iCalculated human biotransformation rate constant using the QSAR model based on dataset 4 from Papa et al. (2018) 
jTotal elimination rate constants (ke) from in vivo rodent database 
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Figure 3.25. Comparison of the whole organism biotransformation rate constants obtained for beta-HCH from the IVIVE 
and QSAR models, along with the total elimination rate constant obtained from in-vivo studies. Plots on the 
graph represent the average kmet values from the IVIVE models (n=3), the kmet values from the QSAR models, 
and average ke values from the in vivo data. 
aCalculated whole organism kmet using the IVIVE-B model                                                                             
bCalculated whole organism kmet using the IVIVE-Ph model                                                                                    
cCalculated whole organism kmet using the IVIVE-Krause & Goss model I (blood flow limitation not considered)                                                                                                                                                         
dCalculated whole organism kmet using the IVIVE-Krause & Goss model II (blood flow limitation considered)                                                                                                                                                             
eCalculated human biotransformation rate constant using the QSAR model from Arnott et al. (2014)  
fCalculated human biotransformation rate constant using the QSAR model based on dataset 1 from Papa et al. (2018)                                                                                                                                                   
gCalculated human biotransformation rate constant using the QSAR model based on dataset 2 from Papa et al. (2018)                                                                                                                                                 
hCalculated human biotransformation rate constant using the QSAR model based on dataset 3 from Papa et al. (2018)                                                                                                                                     
iCalculated human biotransformation rate constant using the QSAR model based on dataset 4 from Papa et al. (2018)                                                                                                                                              
jTotal elimination rate constants (ke) from in vivo rodent database 
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Figure 3.26. Comparison of the whole organism biotransformation rate constants obtained for methoxychlor from the 
IVIVE and QSAR models, along with the total elimination rate constant obtained from in-vivo studies. Plots on 
the graph represent the average kmet values from the IVIVE models (n=3), the kmet values from the QSAR 
models, and average ke values from the in vivo data. 
aCalculated whole organism kmet using the IVIVE-B model                                                                             
bCalculated whole organism kmet using the IVIVE-Ph model                                                                                     
cCalculated whole organism kmet using the IVIVE-Krause & Goss model I (blood flow limitation not considered)                                                                                                                                                         
dCalculated whole organism kmet using the IVIVE-Krause & Goss model II (blood flow limitation considered)                                                                                                                                                             
eCalculated human biotransformation rate constant using the QSAR model from Arnott et al. (2014)  
fCalculated human biotransformation rate constant using the QSAR model based on dataset 1 from Papa et al. (2018)                                                                                                                                                   
gCalculated human biotransformation rate constant using the QSAR model based on dataset 2 from Papa et al. (2018)                                                                                                                                                 
hCalculated human biotransformation rate constant using the QSAR model based on dataset 3 from Papa et al. (2018)                                                                                                                                     
iCalculated human biotransformation rate constant using the QSAR model based on dataset 4 from Papa et al. (2018)                                                                                                                                              
jTotal elimination rate constants (ke) from in vivo rodent database 
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Figure 3.27. Comparison of the whole organism biotransformation rate constants obtained for mono-n-butyl phthalate 
from the IVIVE and QSAR models, along with the total elimination rate constant obtained from in-vivo studies. 
Plots on the graph represent the average kmet values from the IVIVE models (n=3), the kmet values from the 
QSAR models, and average ke values from the in vivo data. 
aCalculated whole organism kmet using the IVIVE-B model                                                                             
bCalculated whole organism kmet using the IVIVE-Ph model                                                                                     
cCalculated whole organism kmet using the IVIVE-Krause & Goss model I (blood flow limitation not considered)                                                                                                                                                         
dCalculated whole organism kmet using the IVIVE-Krause & Goss model II (blood flow limitation considered)                                                                                                                                                             
eCalculated human biotransformation rate constant using the QSAR model from Arnott et al. (2014)  
fCalculated human biotransformation rate constant using the QSAR model based on dataset 1 from Papa et al. (2018)                                                                                                                                                   
gCalculated human biotransformation rate constant using the QSAR model based on dataset 2 from Papa et al. (2018)                                                                                                                                                 
hCalculated human biotransformation rate constant using the QSAR model based on dataset 3 from Papa et al. (2018)                                                                                                                                     
iCalculated human biotransformation rate constant using the QSAR model based on dataset 4 from Papa et al. (2018)                                                                                                                                              
jTotal elimination rate constants (ke) from in vivo rodent database 
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Figure 3.28. Comparison of the whole organism biotransformation rate constants obtained for 4-n-nonylphenol from the 
IVIVE and QSAR models, along with the total elimination rate constant obtained from in-vivo studies. Plots on 
the graph represent the average kmet values from the IVIVE models (n=3), the kmet values from the QSAR 
models, and average ke values from the in vivo data. 
aCalculated whole organism kmet using the IVIVE-B model                                                                             
bCalculated whole organism kmet using the IVIVE-Ph model                                                                                     
cCalculated whole organism kmet using the IVIVE-Krause & Goss model I (blood flow limitation not considered)                                                                                                                                                         
dCalculated whole organism kmet using the IVIVE-Krause & Goss model II (blood flow limitation considered)                                                                                                                                                             
eCalculated human biotransformation rate constant using the QSAR model from Arnott et al. (2014)  
fCalculated human biotransformation rate constant using the QSAR model based on dataset 1 from Papa et al. (2018)                                                                                                                                                   
gCalculated human biotransformation rate constant using the QSAR model based on dataset 2 from Papa et al. (2018)                                                                                                                                                 
hCalculated human biotransformation rate constant using the QSAR model based on dataset 3 from Papa et al. (2018)                                                                                                                                     
iCalculated human biotransformation rate constant using the QSAR model based on dataset 4 from Papa et al. (2018)                                                                                                                                              




Figure 3.29. Linear regression analysis to visualize the relationship between the observed data and predicted whole 
organism biotransformation rate constants from the (a) IVIVE-b model, (b) IVIVE-ph model, (c) IVIVE-Krause & 




Figure 3.30. Linear regression analysis to visualize the relationship between the observed data and predicted whole 
organism biotransformation rate constants from the (a) QSAR (2014) model, (b) QSAR (2018) B1 model, (c) 
QSAR (2018) B2 model, (d) QSAR model (2018) B3 model, and (e) QSAR (2018) B4 model.  
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Table 3.1. Quantitative comparison between the IVIVE and QSAR model 
outputs using the R2 value, P-value of the slope, slope (with slope 
error), root mean square error (RMSE), model bias (MB), and 
standard deviation (upper and lower) of the model bias. These 
metrics apply to the relationship between the model outputs (kmet) 
and in vivo elimination rate constants (ke).  










IVIVE-b 0.754 0.056 0.676 0.223 0.465 1.223 2.036 0.735 













0.768 0.051 0.729 0.231 0.414 1.217 1.968 0.753 
QSAR 
(2014) 
0.671 0.090 0.420 0.170 0.834 0.956 2.441 0.374 
QSAR 
(2018) B1 
0.682 0.085 0.468 0.185 0.901 1.524 2.835 0.820 
QSAR 
(2018) B2 
0.729 0.065 0.459 0.161 0.758 1.127 2.118 0.600 
QSAR 
(2018) B3 
0.557 0.147 0.481 0.248 0.660 0.814 2.411 0.275 
QSAR 
(2018) B4 
0.673 0.089 0.482 0.194 0.700 1.088 2.295 0.516 
 
3.6 Future Directions 
When the kmet values from the IVIVE models were compared to the elimination 
rate constant from in-vivo studies, the results were in reasonable agreement with one 
another. The findings indicate that the solvent phase dosing method followed by an in-
vitro to in-vivo extrapolation could be a useful tool for estimating the biotransformation 
rate constants (for bioaccumulation assessment). However, there are some limitations 
that must be addressed. The in-vivo data that was collected from literature includes 
experiments that were conducted under varying laboratory conditions and there was a 
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lot of variability observed in the in-vivo ke values. It would be more appropriate in future 
studies to have in-vivo data collected from experiments that are conducted under similar 
laboratory conditions. Another limitation with the IVIVE models is that extrahepatic 
biotransformation is not taken into consideration. Future studies should incorporate the 
biotransformation rate constants from extrahepatic organs into the IVIVE models. 
Incorporation of these extrahepatic biotransformation rate constants will further aid in 
preventing the bioaccumulative potential of a substance from being overestimated. 
In addition to the IVIVE models, the solvent phase dosing method is also subject 
to limitations. The first limitation is that when very hydrophobic chemicals end up in an 
aqueous medium (liver homogenate), this could lead to incomplete dissolution. The 
second limitation is that for some of the enzymes found in the S9, the spiking solvent 
could end up competing for the enzyme active site since the solvent has a higher 
concentration than the test chemical. The spiking solvent could even possibly inactivate 
the enzymes (Lee et al., 2016).  The third limitation is that the solvent phase dosing 
method mimics a typical oral administration of a pharmaceutical where the drug initially 
has a high concentration in the blood. For exposures that occur in the environment, the 
organisms are exposed to low concentrations over a prolonged period of time. These 
chemical concentrations could affect the biotransformation rate constant as lower 
concentrations are associated with a higher biotransformation rate constant (as shown in 
the preliminary experiments). The fourth limitation is that the whole organism 
biotransformation rate constant is dependent on the unbound fraction (of incubation 
medium), which is not determined in the solvent phase dosing method, therefore it 
needs to be calculated (adding more uncertainty). Lastly, the solvent phase dosing 
method also comes with analytical challenges that are related to the extraction, 
separation, and analysis of the chemical substances (Lee et al., 2016). There is another 
method known as the sorbent phase dosing method developed by Lee et al. (2012) that 
could potentially overcome these challenges. Future studies should be conducted using 
the sorbent phase dosing method to estimate biotransformation rate constants.  
Additionally, for two of the test chemicals (mono-n-butyl phthalate and 4-n-
nonylphenol), an additional derivatization reaction was required to make the chemicals 
more volatile. If an LC/MS was used instead of a GC/MS, there would be no need for a 
derivatization reaction since it’s not required for the chemical to be in its gas phase (He 
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& Agna, 2019). For future studies, experiments could be conducted using an LC/MS 
rather than a GC/MS. 
Lastly, the QSAR models used in this study were developed for humans and 
compared to IVIVE models that are developed for rats. In the future, QSAR models 
should also be developed for rats and the biotransformation rate constants from rat 
QSAR models should be compared to the biotransformation rate constants obtained 
from the rat IVIVE models and in vivo rat studies.  
Overall, despite the limitations, the solvent phase dosing method followed by an 
in vitro to in vivo extrapolation is a very useful screening tool to determine 
biotransformation rate constants in rats for very hydrophobic test chemicals.  
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4 Conclusion 
In conclusion, the solvent phase dosing method was developed, tested, and 
shown to be a useful approach for measuring biotransformation rate constants in air-
breathing organisms. The substrate depletion experiments that were conducted using 
pyrene, benzo(a)pyrene, hexachlorocyclohexane-beta (beta HCH), methoxychlor, mono-
n-butyl phthalate, and 4-n-nonylphenol were completed successfully and the kr values 
were successfully converted into kmet values. The model performance for all four IVIVE 
models was reasonably similar. However, since simple models (that require less 
biological parameters) are preferred over complex ones, it is suggested that the IVIVE-b 
and IVIVE-Krause & Goss (blood flow not considered) models should be used for 
bioaccumulation assessment. Furthermore, if fewer biological parameters are required, 
bioaccumulation assessment may be extended to a wider array of organisms (both 
aquatic and air breathing) in the near future. Finally, even though the IVIVE-b and IVIVE 
Krause & Goss model is suggested, it is still recommended that the IVIVE models should 
be further developed to include extrahepatic biotransformation.  
It is also suggested that the IVIVE-b and IVIVE-Krause & Goss (blood flow not 
considered) models should be used over the QSAR models for bioaccumulation 
assessment in rats. The QSAR models are developed for humans, and it would be more 
appropriate to use the QSAR models to assess the bioaccumulative potential of 
chemicals in humans. Secondly, for two of the chemicals that were tested in this study, 
the model outputs for most of the QSAR models were much lower than the in-vivo ke 
values (which could lead to miscategorization of a chemical’s bioaccumulative potential). 
The IVIVE model outputs also varied from the in-vivo ke values for some of the test 
chemicals, but the difference was not as large as the difference observed for the QSAR 
model outputs. Thirdly, there was variation observed between the QSAR models and 
this raises the question of which QSAR model would be appropriate to use for 
bioaccumulation assessment. The same question does not arise for the IVIVE models 
since the IVIVE model outputs were fairly similar for all four IVIVE models. Despite the 
limitations, the QSAR model also had some advantages over the IVIVE models. For 
example, the QSAR model does not require in vitro experiments, indicating that chemical 
screening could be quicker and faster. Also, the QSAR models could be further 
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developed (for humans and rats) and calibrated using a larger database when more in-
vivo data is available.   
Due to the limited number of chemicals used in the study, variability in the in vivo 
data, and the IVIVE and QSAR models being developed for different species, a definitive 
conclusion cannot be made regarding which models are more accurate in their 
predictions. However, in this study, it was demonstrated that a combination of the 
solvent phase dosing method followed by an in vitro to in vivo extrapolation is a 
potentially useful approach for screening chemicals for bioaccumulation assessment in 
mammals, compared to how chemicals are currently being assessed (biotransformation 
not considered). When the IVIVE models are further developed by taking extrahepatic 
biotransformation into account, and when QSAR models are developed and available for 
rats, the whole organism biotransformation rates obtained from the IVIVE models or the 
QSAR models could then be used as one of the inputs for the rat BMF model developed 
by Armitage & Gobas (2007) to obtain the biomagnification factor. The BMF could then 
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GC/MS Standard Curves 
 
Figure A.1. Standard curves for benzo(a)pyrene using rat liver S9 from (a) batch 
1, (b) batch 2, (c) and batch 3. Standard curve also developed for 
pyrene that was run parallel with the benzo(a)pyrene experiments 
using rat liver S9 from (d) batch 1, (e) batch 2, (f) and batch 3.  
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Figure A.2. Standard curves for beta-HCH using rat liver S9 from (a) batch 1, (b) 
batch 2, (c) and batch 3. Standard curve also developed for pyrene 
that was run parallel with the beta-HCH experiments using rat liver 
S9 from (d) batch 1, (e) batch 2, (f) and batch 3.  
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Figure A.3. Standard curves for methoxychlor using rat liver S9 from (a) batch 1, 
(b) batch 2, (c) and batch 3. Standard curve also developed for 
pyrene that was run parallel with the methoxychlor experiments 
using rat liver S9 from (d) batch 1, (e) batch 2, (f) and batch 3.  
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Figure A.4. Standard curves for methoxychlor using rat liver S9 from (a) batch 1, 
(b) batch 2, (c) and batch 3. Standard curve also developed for 
pyrene that was run parallel with the methoxychlor experiments 
using rat liver S9 from (d) batch 1, (e) batch 2, (f) and batch 3.  
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Figure A.5. Standard curves for methoxychlor using rat liver S9 from (a) batch 1, 
(b) batch 2, (c) and batch 3. Standard curve also developed for 
pyrene that was run parallel with the methoxychlor experiments 





Protein Content of Rat Liver S9 
 
Figure B.1. The mean blank subtracted absorbance plotted against various 
concentrations of bovine serum albumin (BSA).  
N- number of replicates  
P- Probability value 
Standard error shown in brackets 
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Table B.1. Protein concentrations from the blank corrected absorbance values.  
Sample Replicate 
Volume of 








concentration in 50 




S9 1-1 1 50 1500 0.3000 33.89 50.83 
 2 50 1500 0.3015 34.09 51.14 
 3 50 1500 0.3616 42.32 63.49 
 4 50 1500 0.3248 37.28 55.92 
 5 50 1500 0.3184 36.41 54.61 
S9 1-2 1 50 1500 0.3088 35.09 52.64 
 2 50 1500 0.3240 37.17 55.76 
 3 50 1500 0.3219 36.89 55.33 
 4 50 1500 0.3310 38.13 57.20 
 5 50 1500 0.2925 32.86 49.29 
S9 1-3 1 50 1500 0.3247 37.27 55.90 
 2 50 1500 0.2978 33.58 50.38 
 3 50 1500 0.3173 36.26 54.38 
 4 50 1500 0.2915 32.72 49.08 
 5 50 1500 0.3216 36.84 55.27 
S9 2-1 1 50 1500 0.3224 36.95 55.43 
 2 50 1500 0.3914 46.41 69.61 
 3 50 1500 0.3697 43.43 65.15 
 4 50 1500 0.4066 48.49 72.73 
 5 50 1500 0.3842 45.42 68.13 
S9 2-2 1 50 1500 0.3751 44.17 66.26 
 2 50 1500 0.3853 45.57 68.36 
 3 50 1500 0.3863 45.71 68.56 
 4 50 1500 0.3819 45.11 67.66 
 5 50 1500 0.3902 46.24 69.36 
S9 2-3 1 50 1500 0.3207 36.72 55.08 
 2 50 1500 0.3660 42.93 64.39 
 3 50 1500 0.3661 42.94 64.41 
 4 50 1500 0.3942 46.79 70.18 
 5 50 1500 0.3838 45.37 68.05 
S9 3-1 1 50 1500 0.3427 39.74 59.60 
 2 50 1500 0.3413 39.54 59.32 
 3 50 1500 0.3603 42.15 63.22 
 4 50 1500 0.3494 40.65 60.98 
 5 50 1500 0.3491 40.61 60.92 
S9 3-2 1 50 1500 0.3475 40.39 60.59 
 2 50 1500 0.3670 43.06 64.60 












concentration in 50 




 4 50 1500 0.3370 38.95 58.43 
 5 50 1500 0.3752 44.19 66.28 
S9 3-3 1 50 1500 0.3661 42.94 64.41 
 2 50 1500 0.3351 38.69 58.04 
 3 50 1500 0.3407 39.46 59.19 
 4 50 1500 0.3579 41.82 62.73 
 5 50 1500 0.3781 44.58 66.88 
 
Table B.2. Average protein concentration in rat liver S9 calculated for each 
replicate of each batch.  
Protein concentration in rat S9 (mg/mL) 
 Rat S9 – Batch 1 Rat S9 – Batch 2 Rat S9 – Batch 3 
Rep 1 50.83 52.64 55.90 55.43 66.26 55.08 59.60 60.59 64.41 
Rep 2 51.14 55.76 50.38 69.61 68.36 64.39 59.32 64.60 58.04 
Rep 3 63.49 55.33 54.38 65.15 68.56 64.41 63.22 64.80 59.19 
Rep 4 55.92 57.20 49.08 72.73 67.66 70.18 60.98 58.43 62.73 
Rep 5 54.61 49.29 55.27 68.13 69.36 68.05 60.92 66.28 66.88 
Average 
(n=5) 
55.20 54.04 53.00 66.21 68.04 64.42 60.81 62.94 62.25 
SD 
(n=5) 
5.13 3.13 3.07 6.62 1.17 5.78 1.54 3.29 3.65 
CV 9.3% 5.8% 5.8% 10.0% 1.7% 9.0% 2.5% 5.2% 5.9% 
 
Table B.3. Average of mean protein concentrations in rat liver S9 for each 
batch.  
Rat Liver S9 Batch Batch 1 Batch 2 Batch 3 
Average of Mean Measurement (n=3) 54.08 66.22 62.00 
Standard Deviation (n=3) 1.10 1.81 1.09 





Extraction Efficiency Tests 






















         
HI-S9 
(rep 1) 
12.271 11893 663261 9.992 30398 797970 0.391 0.831 
HI-S9 
(rep 2) 
12.271 9594 538205 9.990 20703 592179 0.463 0.909 
HI-S9 
(rep 3) 
12.270 9324 520280 9.991 18878 542688 0.494 0.959 
HI-S9 
(rep 1) 
12.266 11615 612340 9.998 27840 785805 0.417 0.779 
HI-S9 
(rep 2) 
12.266 16128 832833 9.986 43420 1125807 0.371 0.740 
HI-S9 
(rep 3) 
12.265 19380 953181 9.985 48608 1195618 0.399 0.797 
Hexane 
(rep 1) 
12.276 12304 760602 9.995 35392 1173915 0.348 0.648 
Hexane 
(rep 2) 
12.279 15248 958445 9.996 32524 1137322 0.469 0.843 
Hexane 
(rep 3) 
12.287 12242 833291 9.999 25532 966685 0.479 0.862 
Hexane 
(rep 1) 
12.290 11123 813544 10.000 28369 1069847 0.392 0.760 
Hexane 
(rep 2) 
12.284 15002 1096922 10.001 29213 1082159 0.514 1.014 
Hexane 
(rep 3) 
12.842 15237 1094506 10.000 27618 1052076 0.552 1.040 
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Table C.2. Extraction efficiency calculated for benzo(a)pyrene.  





HI-S9 1 0.831 
0.900 
1.147 
 2 0.909 
 3 0.959 
Hexane 1 0.648 
0.784  2 0.843 
 3 0.862 
HI-S9 1 0.779 
0.772 
0.823 
 2 0.740 
 3 0.797 
Hexane 1 0.760 
0.938  2 1.014 
 3 1.040 
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HI-S9 
(rep 1) 
7.573 485 10497 7.453 1768 27152 0.274 0.387 
HI-S9 
(rep 2) 
7.572 451 9608 7.452 1289 19867 0.350 0.484 
HI-S9 
(rep 3) 
7.572 506 11286 7.452 1744 27195 0.290 0.415 
HI-S9 
(rep 1) 
7.573 481 9950 7.455 1709 25922 0.281 0.384 
HI-S9 
(rep 2) 
7.575 433 8798 7.454 1250 19116 0.346 0.460 
HI-S9 
(rep 3) 
7.574 489 10669 7.454 1692 26163 0.289 0.408 
Hexane 
(rep 1) 
7.571 637 13793 7.45 2361 34769 0.270 0.397 
Hexane 
(rep 2) 
7.572 703 15797 7.451 2068 30966 0.340 0.510 
Hexane 
(rep 3) 
7.573 666 15432 7.45 2261 33077 0.295 0.467 
Hexane 
(rep 1) 
7.573 618 13294 7.452 2291 33438 0.270 0.398 
Hexane 
(rep 2) 
7.574 681 15142 7.453 2002 29410 0.340 0.515 
Hexane 
(rep 3) 




Table C.4. Extraction efficiency calculated for beta-HCH.  










 2 0.484 
 3 0.415 
Hexane 1 0.397 
0.458 
 
 2 0.510 
 3 0.467 





 2 0.460 
 3 0.408 
Hexane 1 0.398 
0.454 
 
 2 0.515 
 3 0.448 
 






















         
HI-S9 
(rep 1) 
11.340 41035 821335 11.394 11905 640284 3.447 1.283 
HI-S9 
(rep 2) 
11.338 49622 970195 11.391 18758 629410 2.645 1.541 
HI-S9 
(rep 3) 
11.336 49544 1008315 11.390 17102 606282 2.897 1.663 
Hexane 
(rep 1) 
11.353 38978 864799 11.414 13598 529188 2.866 1.634 
Hexane 
(rep 2) 
11.351 45446 1152176 11.414 12139 510360 3.744 2.258 
Hexane 
(rep 3) 
11.358 45729 1082621 11.424 11011 501911 4.153 2.157 
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Table C.6. Extraction efficiency calculated for methoxychlor.  









 2 1.541 
 3 1.663 
Hexane 1 1.634  
2.016 
 
 2 2.258 
 3 2.157 
 






















         
HI-S9 
(rep 1) 
8.933 11733 1048427 8.39 10502 797236 1.1172 1.3151 
HI-S9 
(rep 2) 
8.924 15626 1279663 8.385 11436 833504 1.3664 1.5353 
HI-S9 
(rep 3) 
8.922 16182 1333542 8.382 11965 863681 1.3524 1.5440 
Hexane 
(rep 1) 
8.94 15469 1427423 8.398 10734 883832 1.4411 1.6150 
Hexane 
(rep 2) 
8.941 15101 1390943 8.402 10318 847349 1.4636 1.6415 
Hexane 
(rep 3) 
8.947 14099 1356196 8.409 10045 821254 1.4036 1.6514 
 
Table C.8. Extraction efficiency calculated for pyrene.  









 2 1.5353 
 3 1.5440 
Hexane 1 1.6150 1.636 
 
 
 2 1.6415 





Raw Data for Substrate Depletion Experiments 
Table D.1. Detection limits of the GC/MS obtained for each test chemical 
Test Chemical Detection Limit Time Points (mins) 
BaP 0.025 μM 1, 2, 3, 4, 5, 6, 7  
Beta-HCH 0.25 μM 5, 15, 30, 45, 60, 75, 90  
Methoxychlor 0.50 μM 0.5, 1, 2, 3, 4, 5, 7 
Mono-n-butyl phthalate 0.50 μM 2, 4, 6, 8, 10, 12, 14 

















Table D.2. P-values obtained for the test chemicals using simple linear 
regression (active and inactive S9) and multiple linear regression. 
 P-values for Test Chemical 
 SLR (active S9) SLR (inactive S9) MLR 
BaP   
S9 batch 1 2.02E-06 0.109 <0.0001 
S9 batch 2 9.46E-05 0.788 <0.0001 
S9 batch 3 9.26E-08 0.289 <0.0001 
 bHCH  
S9 batch 1 2.68E-05 0.000320 <0.0001 
S9 batch 2 0.000257 6.25E-07 0.180 
S9 batch 3 8.40E-07 0.00171 0.0407 
Methoxychlor                                                           
S9 batch 1 2.89E-08 0.0539 <0.0001 
S9 batch 2 2.26E-07 0.225 <0.0001 
S9 batch 3 1.88E-07 0.381 <0.0001 
Mono-n-butyl phthalate                                                            
S9 batch 1 2.45E-06 0.0658 <0.0001 
S9 batch 2 0.000270 0.0668 <0.0001 
S9 batch 3 0.000398 0.818 <0.0001 
4-n-nonylphenol                                                            
S9 batch 1 0.000256 0.503 0.006 
S9 batch 2 1.14E-05 0.171 <0.0001 






Table D.3. P-values obtained for pyrene that was run alongside the test 
chemicals, using simple linear regression (active and inactive S9) 
and multiple linear regression. 
 P-values for Pyrene 
 SLR (active S9 SLR (inactive S9) MLR 
BaP                                                   
S9 batch 1 1.38E-05 0.549 <0.0001 
S9 batch 2 6.02E-05 0.566 <0.0001 
S9 batch 3 1.73E-06 0.111 <0.0001 
 bHCH  
S9 batch 1 1.03E-06 0.000137 <0.0001 
S9 batch 2 4.06E-05 0.0124 <0.0001 
S9 batch 3 8.23E-07 0.128 <0.0001 
Methoxychlor                                                           
S9 batch 1 6.01E-05 0.537 <0.0001 
S9 batch 2 9.20E-06 0.0866 <0.0001 
S9 batch 3 5.51E-05 0.181 <0.0001 
Mono-n-butyl phthalate                                                            
S9 batch 1 2.40E-07 0.309 <0.0001 
S9 batch 2 3.30E-060 0.0542 <0.0001 
S9 batch 3 4.58E-07 0.266 <0.0001 
4-n-nonylphenol                                                            
S9 batch 1 1.17E-09 0.0602 <0.0001 
S9 batch 2 2.18E-05 0.839 <0.0001 







Table E.1. Preparation of rat liver S9. 
Parameter S9 Batch 1 S9 Batch 2 S9 Batch 3 Reference 
Average Body Weight of Rats 
(g) 
399.7 376.2 438.5 - 
Average Liver Weight of Rats (g) 17.95 13.70 19.24 - 
Total Liver Weight of rats (g) 53.85 41.10 57.73 - 
Liver fraction (g liver/g body 
weight) 
0.045 0.036 0.044 - 
Volume of S9 (mL) 61.0 48.5 69.0 - 
S9 Yield (mL S9/g liver) 1.13 1.18 1.20 - 
Scaling Factor (unitless) 64.35 82.03 77.81 Eqn from Lee et al (2017) 
 
Table E.2. Composition of incubation mixture. 
Parameter S9 Batch 1 S9 Batch 2 S9 Batch 3 Reference 
Protein Concentration in 
Incubation                                   
(mg protein/mL inc mixture) 
1 1 1 - 
Lipid Fraction of Incubation 
Mixture 
(mL lipid/mL inc mixture) 
0.000237 0.000229 0.000188 - 
Protein Fraction of Incubation 
Mixture 
(mL protein/mL inc mixture) 
0.000741 0.000741 0.000741 - 
Water Fraction of Incubation 
Mixture 
(mL water/mL inc mixture) 







Table E.3. Composition of rat liver S9.  
Parameter S9 Batch 1 S9 Batch 2 S9 Batch 3 Reference 
Lipid Content of S9 (g lipid/g S9) 0.011 0.013 0.010 - 
Protein Concentration of S9     
(mg protein/mL S9) 
54.1 66.2 62.0 - 
S9 Protein Content of Liver           
(mg protein/g liver) 
61.3 78.1 74.1 - 
Density of Liver (g liver/mL liver) 1.05 1.05 1.05 
Sohlenius-Sternbeck 
(2006) 
Density of Organism                     
(g organism/mL organism) 
1.05 1.05 1.05 
Sohlenius-Sternbeck 
(2006) 
Density of S9 (g S9/mL S9) 1.05 1.05 1.05 - 
Density of Lipid (g lipid/mL lipid) 0.9 0.9 0.9 - 
Density of Protein                          
(g protein/mL protein) 
1.35 1.35 1.35 - 
Density of Water                           
(g water/mL water) 
1 1 1 - 
Density of Incubation Mixture      
(g inc mixture/mL inc mixture) 
1 1 1 - 
Lipid Fraction of S9                             
(mL lipid/mL S9) 
0.013 0.015 0.012 - 
Protein Fraction of S9                     
(mL protein/mL S9) 
0.0401 0.0490 0.0459 - 
Water Fraction of S9                            
(mL water/mL S9) 
0.947 0.936 0.942 - 
Lipid Concentration of S9                 
(g lipid/mL S9) 










Table E.4. Parameters for the IVIVE-b model  
Parameter Value Unit Reference 
In vitro biotransformation 
rate constant (Kr) 
- hr-1 - 
In vitro biotransformation 
rate constant at 
infinitesimally low 
concentration (Kr, C→0) 
                                 CI 
     Kr, C→0 = Kr/1 - ------------- 
                               CI + KM           
hr-1 Lee et al (2017) 


















Fraction unbound of 
chemical in incubation 
mixture (fu,inc.) 
                             fw,inc 
fu,inc. = ----------------------------------------- 
             fL,inc x KLW + fP,inc x KPW + fw,inc  
unitless Lee et al (2017) 
Maximum in vitro 
biotransformation rate 
constant (Kr*) 
                             Kr, C→0 
                    K*r = ------------ 
                               fu,inc. 
hr-1 Lee et al (2017) 
Body weight (bw) - g Lee et al (2017) 
Liver weight (lw) - g - 
Volume of S9 - mL - 
S9 yield (YS9) 
                        Volume of S9 
              YS9 = ------------------- 
                          Liver weight 
mL S9/g 
liver 
Lee et al (2017) 







Protein concentration in 











Scaling factor (SF) 
                    CP,S9 
          SF= ---------- x YS9 x dH 
                    CP,inc 
unitless Lee et al (2017) 













Parameter Value Unit Reference 






Fraction unbound of 
chemical in liver (fu,L) 
                            fw,H 
fu,H = ------------------------------------------ 
            fL,H x KLW + fP,H x KPW + fw,H 
unitless Lee et al (2017) 
Hepatic biotransformation 
rate constant (kmet,H) 
kmet,H = Kr* x SF x fu,H 
hr-1 Lee et al (2017) 






















Fraction of liver in 
organism (ϕH, v/v) 
                      Liver weight 
       ϕH, v/v = --------------------- 
                      Body weight 
g liver/g 
organism 
Lee et al (2017) 
Fraction of total chemical 
mass in organism that is in 
the liver (MH/MB) 
MH                  fL,H x KLW + fP,H x KPW + fw,H 
---- = ϕH, v/v  x  ---------------------------------     
MB                   fL,B x KLW + fP,B x KPW + fw,B 




kmet = kmet,H x MH/MB 
hr-1 Lee et al (2017) 
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Table E.5. Parameters for the IVIVE-ph model  
Parameter Value Unit Reference 
In vitro biotransformation 
rate constant (Kr) 
- hr-1 - 














In vitro intrinsic clearance 
(CLint) 
                              Kr 
                CLint = --------- 
                             CP,inc 
mL/(h*mg 
protein) 
Lee et al (2017) 
Body weight (bw) - g - 
Liver weight (lw) - g - 
Volume of S9 - mL - 
S9 yield (YS9) 
                         Volume of S9 
              YS9 = ------------------- 
                          Liver weight 
mL S9/g 
liver 
Lee et al (2017) 
S9 protein content in the 
liver (CP,H) 
 




Lee et al (2017) 
Fraction of liver in organism 
(ϕH, w/w) 
                           Liver weight 
          ϕH, w/w = --------------------- 
                           Body weight 
mL liver/mL 
organism 
Lee et al (2017) 
Hepatic intrinsic clearance 
(CLint,H) 
CLint,H = CLint x CP,H x ϕH, w/w mL/(h*g 
organism) 
Lee et al (2017) 
Lipid fraction of liver (fL,H.) - 
mL lipid/mL 
inc mix 
Poulin & Krishnan 
(1996) 









Poulin & Krishnan 
(1996) 
Fraction unbound of 
chemical in incubation 
mixture (fu,inc.) 
                            fw,inc 
fu,inc. = ---------------------------------------- 
            fL,inc x KLW + fP,inc x KPW + fw,inc  
unitless Lee et al (2017) 
Fraction blood through the 
liver (LF) 
0.183 unitless 
Brown et al 
(1997) 




Brown et al 
(1997) 




Lee et al (2017) 
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Parameter Value Unit Reference 
Lipid fraction of blood (fL,Bl) 0.00367 
mL lipid/mL 
blood 
Poulin & Krishnan 
(1996) 













Poulin & Krishnan 
(1996) 
Fraction unbound of 
chemical in blood (fu,Bl) 
                           fw,Bl 
fu,Bl = ------------------------------------------ 
            fL,Bl x KLW + fP,Bl x KPW + fw,Bl 
unitless Lee et al (2017) 
Free fraction correction 
factor (fu) 
                                fu,Bl 
fu = -------- 
                                fu,inc. 
unitless Lee et al (2017) 
Hepatic clearance (CLH) 
                     QH x fu x CLint,H 
          CLH = ---------------------- 
                     QH + fu x CLint,H 
mL/(h*g 
organism) 
Lee et al (2017) 
Volume of distribution (Vd) - 
mL/g 
organism 




                             (CLH) 
                   kmet = --------- 
                               (Vd) 
hr-1 Lee et al (2017) 
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Table E.6. Krause & Goss I (blood flow limitation not considered)  
Parameter Value Unit Reference 
In vitro biotransformation rate 
constant (Kr) 
- hr-1 - 






















Kassay/water = fL,inc. x KLW + fP,inc. x KPW +fw,inc. 
mL water/mL 
inc mix 
Krause & Goss 
(2018) 







Body weight (bw) - g - 
Liver weight (lw) - g - 
Volume of S9 - mL - 
S9 yield (YS9) 
                         Volume of S9 
YS9 = ------------------- 
                         Liver weight 
mL S9/g liver 
Krause & Goss 
(2018) 
Fraction of liver in organism 
(ϕH, w/w) 
                           Liver weight 
ϕH, w/w = --------------------- 
                           Body weight 
mL liver/mL 
organism 
Krause & Goss 
(2018) 
S9 protein content of organism 
(CP,B) 
CP,B = CP,S9 x YS9 x ϕH, w/w mg S9 
protein/g 
organism 
Krause & Goss 
(2018) 
Lipid fraction of organism (fL,B) 0.05 
mL lipid/mL 
organism 
Debruyn & Gobas 
(2006) 






Debruyn & Gobas 
(2006) 






Body-water partition coefficient 
(Kbody/water) 
 
Kbody/water = fL,B. x KLW + fP,B x KPW + fw,B 
mL water/mL 
organism 
Krause & Goss 
(2018) 










                  CP,B         Kassay/water  
kmet = Kr x --------- x ---------------- 
                  CP,inc       Kbody/water 
hr-1 




Table E.7. Krause & Goss I (blood flow limitation considered)  
Parameter Value Unit Reference 
In vitro biotransformation 
rate constant (Kr) 
- hr-1 - 
Protein concentration in 












Protein fraction of 






Water fraction of 






Fraction unbound of 
chemical in incubation 
mixture (fu,inc) 
fw,inc 
fu,inc. = --------------------------------------- 
            fL,inc x KLW + fP,inc x KPW + fw,inc  
unitless 









Krause & Goss 
(2018) 




















Fraction unbound of 
chemical in blood (fu,Bl) 
                            fw,Bl 
fu,Bl = ------------------------------------------ 
            fL,Bl x KLW + fP,Bl x KPW + fW,Bl 
unitless 









Krause & Goss 
(2018) 
Body weight (bw) - g - 
Liver weight (lw) - g - 
Volume of S9 - mL - 
S9 yield (YS9) 
                         Volume of S9 
YS9 = ------------------- 
                          Liver weight 
mL S9/g 
liver 
Krause & Goss 
(2018) 
S9 protein content of 
organism (CP,B) 
 




Krause & Goss 
(2018) 
Fraction blood through the 
liver (LF) 
0.183 unitless 
Brown et al 
(1997) 
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Parameter Value Unit Reference 




Brown et al 
(1997) 




Krause & Goss 
(2018) 
Blood clearance (CLblood) 
                      fU.Bl               CP,B     fW,inc 
            QH x ------  x  Kr x ------ x  ------  
                      fU,inc             CP,inc     fW,Bl 
CLblood = --------------------------------------- 
                      fU.Bl              CP,B       fW,inc 
            QH + ------  x  Kr x ------ x  ------  




Krause & Goss 
(2018) 


































                                    Kblood/water          
           kmet = CLblood x --------------  
                                    Kbody/water      
hr-1 




Table E.8. The mean whole organism biotransformation rate constants (Kmet) 
for pyrene, benzo(a)pyrene, beta-HCH, methoxychlor, mono-n-butyl 
phthalate, and 4-n-nonylphenol obtained from the IVIVE models. The 
model outputs were obtained from the the IVIVE-b, IVIVE-ph, IVIVE-
Krause & Goss (blood flow considered), and IVIVE-Krause & Goss 
(blood flow not considered) model. The mean is reported with the 
































































































Table E.9. The biotransformation rate constants for pyrene, benzo(a)pyrene, 
beta-HCH, methoxychlor, mono-n-butyl phthalate, and 4-n-
nonylphenol obtained from the QSAR models. The model outputs 
were obtained from the QSAR models developed by Arnott et al. 

























0.000168 0.000223 0.00134 0.000443 
Pyrene 4.44 0.083 0.0469 0.158 0.0775 0.0957 
Methoxychor 5.23 0.00241 0.00532 0.00394 0.00452 0.00609 
Benzo(a)pyrene 5.58 0.0504 0.0247 0.0923 0.0431 0.0546 















weight   
Tissue 
analyzed 











200g Plasma 0.117483 hr-1 High 








200g Liver 0.057762 hr-1 High 








200g Plasma 0.117483 hr-1 High 
Ramesh et al 
(2002) 
Benzo(a)pyrene 100 g/m3 Inhalation 
Fischer 
344 
200g Plasma 1.237763 hr-1 High 





Intravenous Wistar 324Â±39g Liver 0.065595 hr-1 Low 





Intravenous Wistar 324Â±39g Liver 0.068176 hr-1 Low 





Intravenous Wistar 324Â±39g Adipose 0.174013 hr-1 High 





Intravenous Wistar 324Â±39g Adipose 0.064479 hr-1 Low 





Intravenous Wistar 324Â±39g Adipose 0.034949 hr-1 Low 





Intravenous Wistar 324Â±39g Adipose 0.031942 hr-1 Low 





Intravenous Wistar 324Â±39g Blood 0.067736 hr-1 Low 





Intravenous Wistar 324Â±39g Blood 0.045701 hr-1 Low 

























Intravenous Wistar 324Â±39g Kidney 1.386294 hr-1 Low 





Intravenous Wistar 324Â±39g Kidney 1.188259 hr-1 Low 





Intravenous Wistar 324Â±39g Liver 0.068853 hr-1 Low 









200-250g Feces 0.06478 hr-1 High 









200-250g Blood 0.038085 hr-1 High 









200-250g Feces 0.085574 hr-1 High 










weight   
Tissue 
analyzed 








Intravenous Wistar 324Â±39g Adipose 0.044009 hr-1 High 





Intravenous Wistar 324Â±39g Adipose 0.053249 hr-1 High 





Intravenous Wistar 324Â±39g Blood 1.155245 hr-1 High 





Intravenous Wistar 324Â±39g Blood 1.66354 hr-1 High 





Intravenous Wistar 324Â±39g Blood 0.101933 hr-1 High 





Intravenous Wistar 324Â±39g Blood 0.058657 hr-1 Low 





Intravenous Wistar 324Â±39g Kidney 3.780872 hr-1 Low 





Intravenous Wistar 324Â±39g Kidney 0.106913 hr-1 High 





Intravenous Wistar 324Â±39g Liver 1.485305 hr-1 High 









200-250g Blood 0.022005 hr-1 High 









200-250g Feces 0.111798 hr-1 High 









200-250g Blood 0.04415 hr-1 High 









200-250g Feces 0.057762 hr-1 High 









200-250g Blood 0.016989 hr-1 High 





Intravenous Wistar 324Â±39g Kidney 0.083512 hr-1 High 





Intravenous Wistar 324Â±39g Kidney 0.091204 hr-1 High 








200g Testis 0.014146 hr-1 High 








300-460g Blood NA Low 








300-460g Blood 2.028704 hr-1 Low 








300-460g Blood NA Low 








300-460g Blood NA Low 








200g Lung 0.057762 hr-1 High 








200g Prostate 0.063013 hr-1 High 





Oral Wistar 400g Blood 0.066001 High 










weight   
Tissue 
analyzed 








Oral Wistar 400g Blood 0.03 High 





Oral Wistar 400g Blood 0.054 High 





Oral Wistar 400g Blood NA Low 





Intravenous Wistar 400g Blood 0.101999 High 





Intravenous Wistar 400g Blood 0.101999 High 
















Oral Wistar 400g Blood 0.060002 High 



























Intravenous Wistar 400g Blood 0.0744 High 





Intravenous Wistar 400g Blood 0.064198 High 





Intravenous Wistar 400g Blood 0.0918 High 
Withey et al 
(1991) 







0.000689 hr-1 Low 
Richter et al 
(1981) 







0.018386 hr-1 Low 
Richter et al 
(1981) 







0.000531 hr-1 Low 
Richter et al 
(1981) 







0.000855 hr-1 Low 
Richter et al 
(1981) 







0.000431 hr-1 Low 
Richter et al 
(1981) 







0.00077 hr-1 Low 
Richter et al 
(1981) 







0.023738 hr-1 Low 






















0.407734 hr-1 High 













0.043322 hr-1 High 










weight   
Tissue 
analyzed 











































0.241515 hr-1 High 

























0.266595 hr-1 High 






















0.110904 hr-1 High 

























0.252054 hr-1 High 













0.062672 hr-1 High 






















0.165035 hr-1 High 













0.148108 hr-1 High 













0.106967 hr-1 High 













0.151342 hr-1 High 













0.235764 hr-1 High 









185-250g Plasma 0.094952 hr-1 Low 










weight   
Tissue 
analyzed 












185-250g Blood 0.09242 hr-1 Low 









185-250g Plasma 0.077016 hr-1 Low 









185-250g Blood 0.067296 hr-1 Low 









185-250g Plasma 0.247553 hr-1 Low 









185-250g Blood 0.154033 hr-1 Low 









185-250g Plasma 0.053319 hr-1 Low 









185-250g Blood 0.046834 hr-1 Low 
Green et al 
(2003) 
 
